healthevidencedigest

Tag: FDA approvals

  • Nexplanon Now Lasts 5 Years: What Women and Providers Need to Know About the FDA’s Extended Approval

    Nexplanon Now Lasts 5 Years: What Women and Providers Need to Know About the FDA’s Extended Approval

    📌 What changed and when January 16, 2026: The FDA approved a supplemental NDA extending Nexplanon’s approved duration from 3 years to 5 years. February 23, 2026: New REMS (Risk Evaluation and Mitigation Strategy) program launched. Nexplanon is now only available through REMS-enrolled providers. August 23, 2026: Deadline by which all providers who insert or remove Nexplanon must complete REMS certification or lose ordering access. If you have a Nexplanon currently: it may now be left in place for up to 5 years from insertion, rather than 3. Discuss your specific timeline with your provider.

    If you have a Nexplanon implant in your arm, there’s a good chance you’ve heard the three-year date coming up like a countdown. Get it out, replace it, or switch to something else. That schedule just changed.

    On January 16, 2026, the FDA approved a supplemental new drug application from Organon extending Nexplanon’s approved duration of use from three years to five years. The approval is based on a clinical trial that followed 399 women through years four and five of continuous implant use and found zero pregnancies and no new safety findings. The same implant, the same arm, two additional years of coverage.

    This post covers the clinical evidence behind the extension, what the new REMS program means for patients and providers, who can benefit from the extended duration and who should still remove at three years, and what to do if you have an implant right now.

    What Nexplanon Is and How It Works

    Nexplanon is a single-rod subdermal contraceptive implant, a small, flexible rod about 4 centimeters long and 2 millimeters wide, roughly the size of a matchstick. It is inserted just under the skin of the inner, non-dominant upper arm by a trained provider. It contains 68 mg of etonogestrel, a synthetic progestin, along with 15 mg of barium sulfate (which makes the implant visible on X-ray) and 0.1 mg of magnesium stearate.

    Etonogestrel is released slowly and continuously from the implant into the bloodstream. It prevents pregnancy through three complementary mechanisms:

    • Suppression of ovulation: the primary mechanism. Etonogestrel inhibits the LH surge that triggers ovulation. No egg released means no pregnancy possible.
    • Thickening of cervical mucus: even if ovulation were to occur, thickened cervical mucus creates a barrier that sperm cannot penetrate effectively.
    • Modification of the endometrium: changes in the uterine lining create an additional unfavorable environment for implantation.

    These three mechanisms together make Nexplanon one of the most effective contraceptive methods available. Its failure rate is less than 0.1% per year, lower than tubal ligation, vasectomy, IUDs, pills, patches, rings, and condoms. Unlike daily pills or monthly rings, it works without any ongoing action on the patient’s part: once inserted, it simply works.

    It is also fully reversible. Fertility returns rapidly after removal, typically within days to weeks, not months. This makes it suitable for patients who want highly effective contraception now but may want to conceive in the future.

    The Clinical Evidence Behind the 5-Year Extension

    The FDA’s extension is based on data from a dedicated clinical trial designed specifically to evaluate contraceptive efficacy and safety during years four and five of use, the period for which no prior approval existed.

    Study design

    NCT04626596 was a multicenter, single-arm, open-label study conducted in the United States. It enrolled 399 women aged 18 to 35 who had been using a Nexplanon implant for exactly 36 months (within a two-week window). Participants continued using the same implant for an additional 24 months, with visits at months 6, 12, 18, and 24 of the extended period. The primary efficacy endpoint was the Pearl Index during years four and five.

    The results

    MeasureResult
    Participants enrolled399 women aged 18 to 35 (mean age 27)
    Pregnancies during years 4 to 5Zero
    Pearl Index (years 4 to 5)0.0 per 100 women-years (95% CI 0.00 to 0.69)
    Mean BMI29.4 kg/m² (range 17.2 to 64.3)
    Participants with BMI 30 or above (obesity)152 participants, 38.1%
    Participants with BMI 40 or above (severe obesity)40 participants, 10.0%
    New safety findings in years 4 to 5None
    Safety profile vs. years 1 to 3Consistent; no new or worsening signals
    Most common adverse event (extended use)Intermenstrual (irregular) bleeding

    Source: NCT04626596. Organon press release January 16, 2026. FDA sNDA approval January 16, 2026.

    The Pearl Index of 0.0, meaning zero pregnancies observed per 100 women-years of use, is the strongest possible contraceptive efficacy result. The upper bound of the 95% confidence interval (0.69) confirms that even accounting for statistical uncertainty, the maximum plausible pregnancy rate during years four and five remains well below 1 per 100 women-years. This is consistent with the established efficacy in years one through three.

    The BMI data is important and clinically underappreciated Weight-based concerns about hormonal contraceptive efficacy are a common patient question. Higher body weight means more body fat, and progestin hormones can be distributed into fat tissue, potentially lowering circulating hormone levels. For some hormonal methods, particularly emergency contraception and some combined pills, this is a documented efficacy concern. For the etonogestrel implant, the clinical trial data has consistently shown maintained efficacy across a wide BMI range. The year 4 to 5 extension study enrolled participants with a mean BMI of 29.4, nearly at the obesity threshold, with a full 38% above BMI 30 and 10% above BMI 40. Zero pregnancies across this population is a meaningful data point for clinicians advising patients with obesity on contraceptive options. The updated label explicitly reflects this diversity.

    Who Benefits From the Extended Duration and Who Should Still Remove at 3 Years

    The 5-year approval is a maximum, not a mandate. Every patient’s situation is individual, and the right duration depends on goals, health status, and preferences.

    Patients likely to benefit from extending to 5 years

    • Those who are satisfied with their current implant experience and have no plans to conceive in the next two years
    • Those who want to avoid an additional insertion/removal procedure, a minor but real burden for some patients
    • Those with irregular access to healthcare where scheduling a replacement at exactly 3 years is difficult
    • Those for whom cost is a factor: one fewer procedure and one fewer device every 5 years versus every 3

    Patients who may prefer removal at or before 3 years

    • Those planning pregnancy in the next year or two
    • Those experiencing side effects (irregular bleeding, headache, mood changes, weight changes) that are troublesome and haven’t improved
    • Those who want to switch to a different contraceptive method
    • Those who have significant medical changes since insertion that affect contraceptive choice or introduce new contraindications

    If You Have a Nexplanon Right Now: What This Means for You

    This is the question most current implant users will want answered directly.

    My implant is approaching or just past 3 years

    The FDA approval means you now have the option to leave your existing implant in place for up to 5 years from the original insertion date, not 5 more years from now. Contact your provider to discuss whether extending is right for you. If you and your provider decide to extend, no procedure is needed; you simply continue as-is. If your implant has already been in place for more than 3 years and you were unaware of the extension, discuss with your provider promptly. The implant must be removed by the end of year 5.

    My implant was recently inserted (within the last year or two)

    When you approach the previously expected 3-year mark, you can now choose to stay with your current implant for an additional 2 years, as long as you remain a good candidate for continued use and have no contraindications at that point. No action needed now.

    My implant was removed and replaced recently, or I’m planning removal

    If you had your implant replaced at or before 3 years, you cannot retroactively extend the old implant. That device has been removed. Your new implant can now be used for up to 5 years from its insertion date. If you scheduled removal before learning about the extension and want to delay, contact your provider’s office to discuss.

    The New REMS Program: What It Is and Why It Exists

    Alongside the duration extension, the FDA required implementation of a new Risk Evaluation and Mitigation Strategy (REMS) for Nexplanon. A REMS is a safety program the FDA uses when a product has known or potential risks that require specific measures beyond standard labeling to manage safely. Nexplanon’s REMS exists specifically to address the risk of complications from improper insertion and removal.

    Why improper insertion is a real concern

    Nexplanon insertion is a minor procedure, but it is a procedure, and getting it wrong has consequences. An implant placed too deeply (intramuscular or beyond) can be difficult or impossible to remove without surgery. Migration, where the implant or a fragment moves from the insertion site, has been reported and sometimes requires more complex removal. Insertion near neurovascular structures can cause nerve damage. The REMS is designed to ensure that every provider who offers Nexplanon has the training to place it correctly, at the recommended depth and location, every time.

    What the REMS requires for providers

    StepWhat’s Required
    1. Register at nexplanonrems.comCreate an account at the REMS portal
    2. Review the Healthcare Provider GuideRead through the updated training materials
    3. Review the Prescribing InformationUpdated to reflect 5-year duration and BMI data
    4. Complete Knowledge Assessment7-question online quiz (~10 minutes total for steps 1 to 4)
    5. Complete Enrollment FormSubmit to receive REMS certification
    6. Complete in-person practical trainingRequired if not previously Organon-trained; includes competency checklist
    7. Report insertion/removal eventsAny complications must be reported using the IRRE form or by calling 1-833-NXP-REMS
    Critical provider deadline: August 23, 2026 Providers who insert or remove Nexplanon must complete REMS certification by August 23, 2026. After this date, providers who have not enrolled will not be able to order or receive Nexplanon for insertion. The enrollment window opened February 23, 2026. For providers who completed Organon’s previous Clinical Training Program, the online REMS enrollment (steps 1 to 5 above) may be sufficient without additional in-person training, depending on whether training history is reflected in the portal. If the system indicates training is required despite prior completion, call 1-833-NXP-REMS (1-833-697-7367). There are no changes to the recommended insertion technique or location. The correct site remains 3 to 5 cm posterior to the sulcus between the biceps and triceps on the inner upper arm. Full guidance is available at nexplanonrems.com.

    For patients: the REMS is a provider-side requirement. You do not need to do anything differently. It does mean that your provider must be REMS-certified to insert or remove your implant. If you are concerned about whether your current provider is enrolled, you can ask them directly or contact Organon’s REMS support line at 1-833-697-7367.

    Safety, Side Effects, and Contraindications

    Common side effects (from years 1 to 3 trials)

    These were reported in at least 5% of clinical trial participants and remain the primary side effects to counsel patients about:

    • Headache (24.9%), the most common
    • Vaginitis (14.5%)
    • Weight increase (13.7%)
    • Acne (13.5%)
    • Breast pain (12.8%)
    • Abdominal pain (10.9%)
    • Pharyngitis/upper respiratory symptoms (10.5%)
    • Changes in menstrual bleeding patterns (the most common reason for discontinuation, at 11.1%)

    Menstrual pattern changes deserve specific mention because they are common and often unexpected. Nexplanon can cause irregular spotting or light bleeding, more frequent bleeding, less frequent bleeding, or complete absence of periods, and the pattern that develops in the first three months is broadly predictive of what to expect going forward. This is not a sign of pregnancy or a problem; it is a normal pharmacological effect of progestin on the endometrium. For patients who find their bleeding pattern unacceptable, removal and method change remains an option at any time.

    Contraindications: who should not use Nexplanon

    Per the updated prescribing information, Nexplanon is contraindicated in patients with:

    • Known or suspected pregnancy
    • Current or past history of thrombosis or thromboembolic disorders
    • Liver tumors (benign or malignant) or active liver disease
    • Undiagnosed abnormal uterine bleeding
    • Known or suspected breast cancer, personal history of breast cancer, or other progestin-sensitive cancer
    • Allergy to any component of Nexplanon

    Drug interactions to know

    Certain medications that induce the CYP3A4 enzyme, including rifampin, some anti-seizure medications (carbamazepine, phenytoin, phenobarbital), and St. John’s Wort, can accelerate etonogestrel metabolism and potentially reduce implant efficacy. Patients starting these medications should discuss contraceptive options with their provider. The implant does not interact with most common medications.

    Cost and Insurance Coverage

    Under the Affordable Care Act, most private insurers are required to cover FDA-approved contraceptive methods without cost-sharing, meaning $0 out-of-pocket for the patient, including the device and the insertion procedure. This applies to Nexplanon. However, coverage details vary by plan, and some plans have grandfathered exemptions or denominational exemptions. It is always worth verifying with your specific insurer.

    For uninsured or underinsured patients, the 5-year duration represents meaningful cost savings, one fewer device and insertion procedure per 10 years of use compared to the 3-year schedule. Title X family planning clinics provide Nexplanon on a sliding-scale fee basis. Organon’s patient support program can assist with coverage navigation; contact information is available at organon.com.

    This extension is part of a broader pattern of evidence-based updates improving access to women’s reproductive healthcare in 2026. For related coverage, see our post on new 2026 cervical cancer self-collection screening guidelines and our overview of GLP-1 medications and PCOS fertility research.

    Do you have questions about your implant or your timeline?

    The FDA’s 5-year extension is a straightforward evidence-based update: the implant keeps working, the safety profile stays consistent, and women with BMI across a wide range continue to be protected. For women with a current implant approaching the 3-year mark, the conversation with your provider is now richer; you have a real choice rather than an automatic expiration date. For providers: the REMS enrollment deadline of August 23, 2026 is actionable now. The enrollment process at nexplanonrems.com takes approximately 10 minutes for those who have completed prior training. Bedsider’s provider resource page and the Reproductive Health Access Project have step-by-step REMS guides for clinical teams.

    Sources

    Organon press release: Organon Announces FDA Approval of sNDA Extending Duration of Use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque. January 16, 2026.

    FDA updated prescribing information: NEXPLANON Prescribing Information (2026). accessdata.fda.gov.

    Clinical trial registration: NCT04626596: Study to Assess Contraceptive Efficacy and Safety of ENG Implant Beyond 3 Years of Use. ClinicalTrials.gov.

    Contemporary OB/GYN: FDA approves 5-year use for etonogestrel implant 68 mg contraceptive. contemporaryobgyn.net. January/March 2026.

    ReproHH (UCSF): FDA Approves Updated Nexplanon Label and Launches New REMS: What to Know. reprohh.ucsf.edu. February 2026.

    Reproductive Health Access Project: Contraceptive Pearl: New FDA REMS Requirement on Nexplanon. reproductiveaccess.org. March 2026.

    Bedsider for providers: Nexplanon REMS Requirements: What Providers Need to Know. providers.bedsider.org. March 2026.

    Organon Pro (REMS FAQs): FAQs: NEXPLANON for HCPs. organonpro.com.

    REMS enrollment: nexplanonrems.com. REMS support: 1-833-NXP-REMS (1-833-697-7367)

    ACOG LARC resource: Long-Acting Reversible Contraception: Intrauterine Device and Implant. ACOG.

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about contraceptive methods, including whether to extend Nexplanon use to 5 years, should be made in consultation with a qualified healthcare provider who can account for your individual health history and circumstances.
  • A Historic First: FDA Approves Immunotherapy for Platinum-Resistant Ovarian Cancer — What the KEYNOTE-B96 Data Tells Us

    A Historic First: FDA Approves Immunotherapy for Platinum-Resistant Ovarian Cancer — What the KEYNOTE-B96 Data Tells Us

    📌 The essentials On February 10, 2026, the FDA approved pembrolizumab (Keytruda, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (combined positive score, or CPS, of at least 1). The approval covers patients who have received one or two prior lines of systemic therapy. This is the first FDA-approved immunotherapy for ovarian cancer in history. The clinical basis: KEYNOTE-B96/ENGOT-ov65 (NCT05116189), a randomized, double-blind, placebo-controlled Phase 3 trial in 643 patients, showed median overall survival of 18.2 months versus 14.0 months with placebo (HR 0.76; p=0.0053) in the PD-L1 CPS of 1 or higher population. The first statistically significant OS benefit ever demonstrated by an immune checkpoint inhibitor in ovarian cancer. A companion diagnostic requirement: Tumor testing with the PD-L1 IHC 22C3 pharmDx assay confirming CPS of 1 or higher is required before treatment. This is a requirement, not a recommendation.

    Ovarian cancer has resisted immunotherapy for decades. Every major trial of immune checkpoint inhibitors in this disease came back negative or borderline, results that didn’t survive longer follow-up. The field watched other gynecologic cancers, particularly cervical and endometrial, respond to PD-1 blockade while ovarian cancer remained stubbornly outside that story.

    That changed on February 10, 2026.

    The FDA approved pembrolizumab (Keytruda, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS of at least 1). The approval covers patients who have received one or two prior lines of systemic therapy.

    It is the first FDA-approved immunotherapy for ovarian cancer in history.

    This post covers what platinum resistance means and why it matters, what KEYNOTE-B96 showed across its primary and key secondary endpoints, how to read the survival data carefully, what the companion diagnostic approval means in practice, and what questions are still open.

    Platinum Resistance: Why This Setting Is So Hard to Treat

    Most women with advanced ovarian cancer respond well to their first-line treatment, typically surgery followed by platinum-based chemotherapy, often combined with a taxane and increasingly with PARP inhibitors as maintenance. Response rates in the frontline setting can exceed 70 to 80%.

    The problem is recurrence. About 70 to 80% of patients with advanced ovarian cancer relapse after initial treatment. When recurrence happens, the most important prognostic factor is how quickly it occurs after the last platinum therapy. Patients whose disease progresses more than six months after platinum are classified as platinum-sensitive and can be retreated with platinum. Patients whose disease progresses within six months are classified as platinum-resistant.

    Platinum resistance is a watershed moment in the treatment arc. Non-platinum options, including weekly paclitaxel, pegylated liposomal doxorubicin, gemcitabine, and bevacizumab, produce response rates in the 10 to 20% range and median progression-free survival measured in months. Median overall survival in platinum-resistant ovarian cancer has historically ranged from roughly 12 to 16 months. These patients carry significant unmet need, and the disease is hard to control with anything currently available.

    That is the context in which the KEYNOTE-B96 results need to be understood.

    The KEYNOTE-B96 Trial: Design and Patient Population

    KEYNOTE-B96 (also known as ENGOT-ov65, NCT05116189) was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial enrolling 643 patients with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Eligibility required:

    • Platinum-resistant disease, defined as radiographic progression within six months of the last platinum-based regimen
    • One or two prior lines of systemic therapy for ovarian carcinoma
    • At least one prior platinum-based chemotherapy regimen
    • Measurable disease by RECIST v1.1

    Patients with primary platinum-refractory disease, meaning progression during or immediately after first-line platinum, were excluded.

    Patients were randomized 1:1 to pembrolizumab plus weekly paclitaxel (80 mg/m² on days 1, 8, and 15 of each 3-week cycle), with or without bevacizumab (10 mg/kg every two weeks), or placebo plus the same backbone. Bevacizumab use was at investigator’s discretion and was a stratification factor. Stratification also included geographic region and PD-L1 expression by CPS.

    The primary endpoint was investigator-assessed progression-free survival (PFS) by RECIST v1.1, evaluated first in the PD-L1 CPS of 1 or higher population, then in the ITT population. Overall survival was a key secondary endpoint.

    What is PD-L1 CPS and why does it determine eligibility? PD-L1 Combined Positive Score (CPS) measures PD-L1 protein expression across tumor cells, tumor-associated lymphocytes, and macrophages. A CPS of 1 or higher means at least 1 PD-L1-staining cell per 100 tumor cells was detected. This is a relatively low threshold: in KEYNOTE-B96, approximately 466 of 643 patients (roughly 72%) had CPS of 1 or higher. The FDA approval is restricted to CPS of 1 or higher patients, where both PFS and OS benefits were demonstrated. The ITT population also showed significant PFS improvement, but the OS benefit was most clearly established in the CPS of 1 or higher group. This matters in practice: before receiving this regimen, a patient’s tumor must be tested with the FDA-approved companion diagnostic, the PD-L1 IHC 22C3 pharmDx assay, and return a CPS of 1 or higher result. This is a requirement, not a recommendation.

    The Results: Progression-Free Survival and Overall Survival

    The trial conducted two pre-specified interim analyses. The second (IA2), with a data cutoff of May 5, 2025, was presented at ESMO Congress 2025 in Berlin in October 2025 and formed the basis for the February 2026 FDA approval. Final OS data were subsequently published in The Lancet in April 2026.

    Progression-Free Survival

    In the PD-L1 CPS of 1 or higher population (n=466), median PFS was 8.3 months with pembrolizumab versus 7.2 months with placebo, with a hazard ratio of 0.72 (95% CI 0.58 to 0.89; p=0.0014). The 12-month PFS rate was 35.2% for pembrolizumab versus 22.6% for placebo.

    In the ITT population (all 643 patients), median PFS was 8.3 versus 6.4 months (HR 0.70; 95% CI 0.58 to 0.84; p less than 0.0001), with 12-month PFS rates of 33.1% versus 21.3%.

    These are statistically significant and clinically meaningful improvements in a setting where six months of progression-free survival is often considered a reasonable benchmark.

    Overall Survival

    Among the 466 PD-L1 CPS of 1 or higher patients, median OS was 18.2 months in the pembrolizumab arm versus 14.0 months with placebo, a hazard ratio of 0.76 (95% CI 0.61 to 0.94; p=0.0053). The 12-month OS rate was 69.1% versus 59.3%. The 18-month OS rate was 51.5% versus 38.9%.

    A four-month improvement in median OS. The first statistically significant overall survival benefit ever shown by an immune checkpoint inhibitor in ovarian cancer.

    EndpointPembrolizumab plus chemoPlacebo plus chemoHR (95% CI)P-value
    Median PFS (CPS of 1 or higher)8.3 months7.2 months0.72 (0.58 to 0.89)0.0014
    Median PFS (ITT)8.3 months6.4 months0.70 (0.58 to 0.84)less than 0.0001
    Median OS (CPS of 1 or higher)18.2 months14.0 months0.76 (0.61 to 0.94)0.0053
    12-month OS (CPS of 1 or higher)69.1%59.3%——
    18-month OS (CPS of 1 or higher)51.5%38.9%——

    Source: KEYNOTE-B96/ENGOT-ov65 Phase 3 trial, IA2 (data cutoff May 5, 2025). Final OS data: The Lancet, April 2026. FDA approval: February 10, 2026.

    How to Read These Numbers Carefully

    A four-month improvement in median OS is real and clinically meaningful in this setting, particularly given the historical absence of any survival benefit from immunotherapy in ovarian cancer. But it is worth understanding what the numbers do and don’t tell us.

    The hazard ratio of 0.76 means that at any given point during the trial, patients in the pembrolizumab arm had a 24% lower risk of death than those in the placebo arm. This is not a cure. It is a reduction in the rate of events that translates into prolonged survival for a meaningful portion of patients. The 18-month OS rate shifting from 38.9% to 51.5% is the clearest way to see this: at 18 months, roughly one in eight additional patients were alive in the pembrolizumab arm compared to the placebo arm.

    The approval is restricted to CPS of 1 or higher. About 72% of patients in KEYNOTE-B96 met this threshold, so most platinum-resistant ovarian cancer patients would be eligible for testing, but not all will test positive.

    Median survival describes the midpoint of the distribution, not individual patient outcomes. Some patients in the pembrolizumab arm had substantially longer survival than 18 months. The final OS data from The Lancet publication provides a clearer view of the tail of the survival curve, which will help clarify whether there is a subset of patients with especially durable benefit, the pattern that checkpoint inhibitors sometimes produce in other tumors.

    The Companion Diagnostic: What the PD-L1 Test Means in Practice

    The FDA simultaneously approved the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies) as a companion diagnostic for identifying eligible patients. Tumor PD-L1 testing confirming CPS of 1 or higher is required before treatment, not optional.

    The 22C3 pharmDx assay is the same companion diagnostic used in pembrolizumab approvals across multiple other tumor types, including cervical, endometrial, esophageal, and gastric cancers. At most academic medical centers and major oncology practices, this test is already part of the standard pathology workflow. At community oncology centers or in lower-resource settings, access to and turnaround time on the assay is a practical consideration worth discussing with the treating team.

    Tumor tissue for PD-L1 testing can come from the original diagnosis or a recurrence biopsy. Given that PD-L1 expression can change with disease progression, some oncologists may prefer more recently collected tissue, though the label does not mandate this.

    What about bevacizumab? The approved regimen is pembrolizumab plus paclitaxel, with or without bevacizumab. Bevacizumab (Avastin) is an anti-VEGF antibody with established activity in ovarian cancer, including in the platinum-resistant setting. Its use in KEYNOTE-B96 was at investigator discretion and was a stratification factor. Patients with contraindications to anti-VEGF therapy, such as certain cardiovascular risk factors, recent major surgery, a history of GI perforation, or significant proteinuria, can receive pembrolizumab plus paclitaxel without bevacizumab. Review the full Keytruda prescribing information for complete contraindication guidance.

    Why Previous Immunotherapy Trials in Ovarian Cancer Failed, and Why This One Didn’t

    The history of checkpoint inhibitor trials in ovarian cancer before KEYNOTE-B96 is largely a story of negative results. Earlier Phase 3 trials, including atezolizumab plus chemotherapy in frontline and maintenance settings, did not demonstrate meaningful survival improvements. Single-agent anti-PD-1 trials showed modest response rates of 10 to 15% in unselected ovarian cancer patients.

    Several factors likely contributed. Ovarian cancer has a relatively immunosuppressive tumor microenvironment, with high regulatory T cell infiltration, immunosuppressive cytokines, and ascites fluid that dampens immune activity. Tumor mutational burden is generally lower than in cancers like melanoma or lung cancer that respond robustly to checkpoint inhibitors. And earlier trials often did not select for PD-L1 expression.

    KEYNOTE-B96 made design choices that may have improved its chances. The combination with weekly paclitaxel, a metronomic dosing schedule thought to have immunomodulatory properties alongside its cytotoxic effects, may have made the tumor microenvironment more permissive to immune infiltration. The CPS of 1 or higher selection enriched for a more immunologically accessible population. These are mechanistic hypotheses with biological plausibility, not proven causal explanations, but they provide a rational basis for why this combination in this specific population succeeded where broader efforts did not.

    Safety: What Patients and Clinicians Need to Know

    The safety profile of the pembrolizumab combination in KEYNOTE-B96 was consistent with prior pembrolizumab trials. No new safety signals were identified.

    Pembrolizumab carries immune-mediated adverse reactions as a class, the consequence of broadly activating the immune system. These can affect virtually any organ system.

    Key immune-mediated risks:

    • Pneumonitis: inflammation of the lungs; monitor for new or worsening respiratory symptoms
    • Colitis: diarrhea and abdominal pain; may require corticosteroids or discontinuation
    • Hepatitis: elevated liver enzymes; regular LFT monitoring during treatment
    • Endocrinopathies: thyroid dysfunction, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis
    • Nephritis: elevated creatinine; monitor renal function
    • Dermatologic reactions: rash, rare severe skin reactions including Stevens-Johnson syndrome

    Most immune-mediated adverse reactions are manageable with corticosteroids if caught early. The prescribing information outlines detailed management algorithms, including when to hold versus permanently discontinue pembrolizumab.

    Other warnings:

    Infusion-related reactions: fever, chills, hypotension, and bronchospasm are possible. Standard premedication and monitoring protocols apply.

    Embryo-fetal toxicity: pembrolizumab can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for at least four months after the final dose.

    Dosing:

    The approved pembrolizumab dose is 200 mg IV every three weeks or 400 mg IV every six weeks, until disease progression, unacceptable toxicity, or up to 24 months of treatment. Pembrolizumab is administered before paclitaxel and bevacizumab when given on the same day.

    Keytruda Qlex, a subcutaneous formulation combining pembrolizumab with berahyaluronidase alfa-pmph, was also approved. The subcutaneous dose is 395 mg/4,800 units every three weeks or 790 mg/9,600 units every six weeks, and can be administered in approximately five to ten minutes rather than the 30-minute IV infusion. For patients receiving multiple cycles over months of treatment, this is a real reduction in clinic time.

    Open Questions and the Road Ahead

    The KEYNOTE-B96 approval opens a new chapter in ovarian cancer treatment, but several clinical questions will shape how the approval is used in practice.

    How durable is the benefit?

    The final OS data in The Lancet provides longer follow-up than the interim analysis. The field will be watching for a favorable tail on the survival curve, the pattern suggesting a subset of patients achieve especially prolonged disease control, which checkpoint inhibitors produce in some tumor types.

    Does PD-L1 CPS fully capture who responds?

    CPS of 1 or higher is a broad threshold. Within the PD-L1-positive population there is likely meaningful heterogeneity in response. Future work will examine whether higher CPS thresholds, tumor mutational burden, microsatellite instability status, or tumor-infiltrating lymphocyte density can further refine patient selection.

    What about earlier lines of therapy?

    The positive KEYNOTE-B96 result will prompt investigators to ask whether pembrolizumab-containing regimens have a role in the frontline or maintenance setting in ovarian cancer. Several trials are already exploring this. The data in those settings will need to be evaluated on their own terms.

    Sequencing after progression on this regimen:

    The approval covers patients after one or two prior regimens. What comes next for patients who progress on pembrolizumab plus chemotherapy? The treatment landscape at third or later lines remains difficult, and ongoing trials will need to address sequencing questions. ClinicalTrials.gov is the primary resource for identifying open studies.

    Project Orbis: A Global Review Pathway This approval was reviewed under Project Orbis, an FDA Oncology Center of Excellence initiative enabling concurrent submission and review across multiple international regulatory agencies. For KEYNOTE-B96, FDA collaborated with Australia’s Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. Project Orbis doesn’t mean all countries approve simultaneously; each agency makes its own decision. But it creates a framework for data sharing that can accelerate global access. The designation signals that review is underway or completed in partner countries.

    What This Means for Patients With Platinum-Resistant Ovarian Cancer

    For patients who have progressed after one or two lines of therapy and are now facing platinum-resistant disease, the conversation with their oncologist includes a genuinely new option for the first time. Pembrolizumab plus paclitaxel, with or without bevacizumab, is not a marginal refinement. It is the first regimen to improve overall survival in this population in a Phase 3 trial.

    The first step is PD-L1 testing. Patients whose disease has not been recently biopsied may want to discuss with their oncologist whether fresh tissue for biomarker testing is feasible and clinically appropriate at the time of progression.

    For related coverage of how immunotherapy and ADC approvals are expanding across gynecologic and breast cancers in 2026, see our posts on Dato-DXd in triple-negative breast cancer, vepdegestrant and the first PROTAC approval in oncology, and what the FDA’s contrasting decisions on camizestrant and vepdegestrant reveal about the future of ESR1-guided treatment.

    Patient advocacy organizations with resources for ovarian cancer include the Ovarian Cancer Research Alliance, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancer. All three maintain clinical trial databases and physician directories. Patients interested in trials evaluating pembrolizumab in earlier-line ovarian cancer settings can search for open studies at ClinicalTrials.gov.

    Sources

    FDA approval: FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. February 10, 2026. FDA.gov.

    KEYNOTE-B96 trial registration: NCT05116189. ClinicalTrials.gov.

    ESMO 2025 abstract: Colombo N et al. Pembrolizumab vs Placebo Plus Weekly Paclitaxel plus/minus Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer. LBA3. ESMO Congress 2025, Berlin, October 2025.

    Final OS publication: KEYNOTE-B96/ENGOT-ov65 final overall survival analysis. The Lancet. April 2026.

    Merck press release: Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival. May 2025. merck.com.

    OncLive approval coverage: KEYNOTE-B96 Approval Reinforces the Shift Toward Biomarker-Driven Treatment in Recurrent PROC. OncLive. March 2026.

    Clinical review: The role of chemo-immunotherapy in platinum-resistant ovarian cancer in light of the KEYNOTE-B96 trial. PubMed Central.

    Keytruda prescribing information: Keytruda (pembrolizumab) and Keytruda Qlex Prescribing Information. Merck. 2026.

    Keytruda Qlex FDA approval: FDA approves pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for multiple indications.

    Companion diagnostic: PD-L1 IHC 22C3 pharmDx. FDA list of cleared or approved companion diagnostics.

    Project Orbis: Project Orbis. FDA Oncology Center of Excellence.

    Patient resources: Ovarian Cancer Research Alliance | National Ovarian Cancer Coalition | Foundation for Women’s Cancer | ClinicalTrials.gov

    Disclaimer: Health Evidence Digest provides general health and regulatory information for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for ovarian cancer should be made in consultation with a board-certified gynecologic oncologist experienced in managing platinum-resistant disease.
  • IZERVAY Can Now Be Used Beyond 12 Months. The Two-Year GATHER2 Data That Earned That Label Change and What It Means for Patients with Geographic Atrophy.

    IZERVAY Can Now Be Used Beyond 12 Months. The Two-Year GATHER2 Data That Earned That Label Change and What It Means for Patients with Geographic Atrophy.

    📌 The essentials On February 13, 2025, the FDA approved an expanded label for IZERVAY (avacincaptad pegol intravitreal solution, Astellas Pharma), removing the 12-month treatment duration limit that was part of the original August 2023 approval. The drug is now approved without restriction on duration of treatment. The clinical basis: Two-year data from the GATHER2 Phase 3 trial (NCT04435366), published in Ophthalmology in December 2025, showing that the treatment benefit of IZERVAY more than doubled between year one and year two of continuous treatment. The year-two data also showed that every-other-month (EOM) dosing maintained efficacy comparable to monthly dosing, offering a meaningful reduction in treatment burden for patients who tolerate the drug. Who this matters for: Patients currently on IZERVAY approaching or past the previous 12-month ceiling, and patients with geographic atrophy (GA) secondary to AMD who have not yet started treatment and are weighing their options.

    Geographic atrophy is the advanced form of dry age-related macular degeneration, and until 2023, it had no approved treatments. Patients watched their central vision deteriorate with nothing to offer but AREDS2 vitamins to slow progression to the advanced stage. That changed when the FDA approved two complement inhibitors in the same year: pegcetacoplan (Syfovre, Apellis) in February 2023 and avacincaptad pegol (IZERVAY, Astellas) in August 2023. For the first time, retinal specialists had tools, modest ones but real ones, to slow the growth of GA lesions.

    The original IZERVAY approval carried a limitation: the label authorized treatment for up to 12 months. That ceiling reflected the data available at the time of initial approval. But the GATHER2 Phase 3 trial continued beyond that point, and its two-year results are now in.

    On February 13, 2025, the FDA approved an expanded label for IZERVAY, removing the 12-month dosing limit. The drug is now approved without a restriction on duration of treatment. The updated label is based on two-year data from GATHER2 showing that the benefit of IZERVAY continued to grow over time, more than doubling between year one and year two.

    This post covers what geographic atrophy is and why treatment is difficult, how IZERVAY works, what the full GATHER2 data shows through two years, what the label change means in practice, and how IZERVAY sits in the context of the two available GA treatments.

    Geographic Atrophy: The Disease Behind the Drug

    Age-related macular degeneration (AMD) is the leading cause of central vision loss in adults over 50 in the developed world, affecting the macula, the small, high-acuity central area of the retina responsible for reading, recognizing faces, and driving. AMD progresses along a spectrum from early (drusen deposits, pigment changes) through intermediate to advanced forms.

    Advanced AMD has two forms. Neovascular AMD (wet AMD) involves abnormal blood vessel growth beneath the retina, causing rapid vision loss that is treatable with anti-VEGF injections. Geographic atrophy (GA), the dry advanced form, involves progressive loss of retinal pigment epithelial (RPE) cells, photoreceptors, and the underlying choriocapillaris. The name comes from the appearance of the lesions on imaging: well-demarcated, map-like areas of atrophy that expand over time. GA progresses slowly but relentlessly, with no reversal of lost retinal tissue.

    An estimated one million Americans have geographic atrophy. As GA expands toward the central fovea, it causes an increasingly large, permanent blind spot in central vision. The impact on reading, driving, and face recognition is severe. Because the process is slow and does not cause the sudden dramatic vision loss seen in wet AMD, patients sometimes do not realize the extent of their deterioration until it is substantial.

    Why GA is hard to treat and why lesion growth is the primary endpoint The complement system plays a central role in GA pathogenesis. Genome-wide association studies have identified complement factor H (CFH) variants as the strongest genetic risk factor for advanced AMD. Complement dysregulation causes chronic inflammation, drusen deposition, and formation of the membrane attack complex (MAC), which destroys RPE cells and photoreceptors. Because no treatment can restore dead retinal cells, approved therapies for GA are designed to slow the rate of lesion expansion, measured by area of GA on fundus autofluorescence imaging, rather than improve vision directly. Neither of the two approved GA drugs has demonstrated statistically significant improvement in best-corrected visual acuity (BCVA) in their pivotal trials. This is not a failure of the drugs; it reflects the biology of a slowly progressive disease where even a meaningful structural benefit may not translate to measurable visual gains over 12 to 24 months. The FDA accepted lesion growth rate as an acceptable primary endpoint for approval. The European Medicines Agency took a different position, declining to approve Syfovre on the grounds that lesion slowing was not sufficient evidence of clinically meaningful patient benefit. That regulatory distinction is worth understanding when comparing how this drug class is viewed globally.

    How IZERVAY Works: C5 Inhibition and the Complement Cascade

    IZERVAY (avacincaptad pegol) is a pegylated RNA aptamer, a chemically modified oligonucleotide rather than a monoclonal antibody, that specifically inhibits complement protein C5. Understanding why C5 is the target and what an RNA aptamer is helps make sense of both the mechanism and the safety profile.

    The complement cascade and C5’s role

    The complement system is a network of proteins that form a critical arm of innate immunity. When activated, the cascade converges on two central reactions: cleavage of complement component C3 into C3a and C3b, and then cleavage of C5 into C5a and C5b. C5a is a potent pro-inflammatory mediator. C5b initiates assembly of the membrane attack complex (MAC), a protein complex that punches holes in cell membranes and destroys them. In GA, chronic overactivation of the complement pathway leads to persistent MAC formation and progressive destruction of RPE cells and photoreceptors.

    IZERVAY blocks C5 cleavage, preventing formation of both C5a and C5b and therefore preventing downstream MAC assembly. Because C5 sits near the terminal end of the cascade, inhibiting it preserves upstream complement activity, including C3 function and opsonization, while specifically blocking the terminal destructive pathway implicated in GA.

    What makes avacincaptad pegol an RNA aptamer

    Unlike the monoclonal antibodies used in wet AMD (ranibizumab, bevacizumab, aflibercept), avacincaptad pegol is an RNA aptamer: a short, precisely folded strand of chemically modified RNA that binds its target protein, complement C5, with high specificity. The pegylation (attachment of polyethylene glycol chains) extends its half-life in the eye and improves stability. It is delivered as a 100 μL intravitreal injection directly into the vitreous humor of the eye.

    C5 vs. C3: Two targets, two drugs IZERVAY (avacincaptad pegol) targets C5, near the terminal end of the complement cascade. Syfovre (pegcetacoplan) targets C3, which sits upstream at the convergence of all three complement activation pathways (classical, alternative, and lectin). The theoretical advantage of C5 inhibition is that it preserves upstream C3 activity, including opsonization of pathogens and apoptotic cells, while blocking the terminal destructive MAC. The theoretical advantage of C3 inhibition is broader suppression of the cascade. Neither advantage has been definitively demonstrated to be clinically superior in head-to-head data. What is clear is that the two drugs have meaningfully different safety profiles, particularly regarding intraocular inflammation. Rare but serious cases of retinal vasculitis have been reported with pegcetacoplan in post-marketing surveillance. That signal has not been observed with avacincaptad pegol in clinical trials.

    The GATHER Trial Program: From Phase 2/3 to the Two-Year Label Change

    The evidence base for IZERVAY rests on two Phase 3 trials: GATHER1 and GATHER2. Both evaluated monthly 2 mg intravitreal injections of avacincaptad pegol versus sham in patients with non-center-point-involving GA secondary to AMD. The primary endpoint in both was GA lesion growth rate measured by fundus autofluorescence.

    GATHER1: Initial evidence and original approval

    GATHER1 (NCT02686658) enrolled 286 patients across 12 months of treatment. The trial evaluated doses of 2 mg and 4 mg versus sham. The 2 mg dose reduced GA lesion growth rate by 27.4% (p=0.0072) and the 4 mg dose by 27.8% (p=0.0051) compared with corresponding sham groups. The 2 mg dose was selected for further development based on its favorable benefit-risk profile. These data, combined with GATHER2, formed the basis of the original August 2023 FDA approval.

    GATHER2: The Phase 3 confirmatory trial through two years

    GATHER2 (NCT04435366) was a randomized, double-masked, sham-controlled, multicenter Phase 3 trial enrolling 448 patients. For the first 12 months, patients received monthly IZERVAY 2 mg or sham. At month 12, patients originally assigned to IZERVAY were re-randomized to continue monthly (EM, n=96) or switch to every-other-month dosing (EOM, n=93). Sham patients continued on sham through year two (n=203).

    TimepointIZERVAY vs. Sham: GA growth rate reductionStatistical significance
    Year 1 (Month 12)14% reduction in monthly group vs. shamp less than 0.01 (primary endpoint met)
    Year 2 (Month 24), every-month dosing (EM)Treatment benefit continued; total benefit more than doubled vs. year 1Maintained vs. sham
    Year 2 (Month 24), every-other-month (EOM)Treatment benefit maintained at comparable level to EMMaintained vs. sham
    Onset of benefitObserved as early as 6 monthsStatistically significant from month 6 onward

    Source: Khanani AM et al. Ophthalmology. Published online December 15, 2025. doi:10.1016/S0161-6420(25)00790-0

    The two-year findings carry a clinically important message: the benefit of IZERVAY did not plateau or diminish with continued treatment. It grew. The reduction in GA growth rate more than doubled between year one and year two, suggesting that the treatment effect compounds over time as the drug continues to suppress terminal complement activation and MAC formation. This is consistent with the biology: continuous inhibition of the destructive pathway progressively spares more retinal tissue relative to an untreated eye.

    The every-other-month data in year two is also practically significant. Reducing injection frequency from monthly to bimonthly without loss of efficacy substantially reduces the treatment burden for patients who are tolerating therapy. Fewer clinic visits and injections per year is a meaningful quality-of-life consideration for an older patient population managing multiple chronic conditions.

    Safety Through Two Years: What the GATHER2 Data Shows

    The safety profile of IZERVAY over two years in GATHER2 was consistent with year-one observations, with no new or significant signals. For patients and prescribers making long-term treatment decisions, the two-year safety picture matters as much as the efficacy data.

    Adverse eventIZERVAY (2-yr data)Clinical note
    Endophthalmitis (eye infection)1 case (culture-positive, non-serious)Rare; inherent risk of any intravitreal injection
    Intraocular inflammation (serious)0 casesNo serious IOI; no cases of retinal vasculitis
    Ischemic optic neuropathy0 casesSafety signal seen with Syfovre; absent here
    Choroidal neovascularization (CNV)/wet AMD conversionIZERVAY: 11.6% vs. Sham: 9.0%Small numerical increase; class effect for complement inhibitors
    Conjunctival hemorrhage (most common AE)CommonTypical injection-site reaction; self-limiting
    Increased intraocular pressureCommonTransient; monitored post-injection
    Blurred visionCommonTypically transient

    The absence of serious intraocular inflammation, retinal vasculitis, and ischemic optic neuropathy over two years is a notable feature of the IZERVAY safety profile. These events have been reported in post-marketing surveillance with pegcetacoplan (Syfovre), and their absence in GATHER2 is meaningful context for the prescribing decision.

    The small numerical increase in choroidal neovascularization (wet AMD conversion) with IZERVAY, 11.6% versus 9% in the sham group, is a known class effect of complement inhibition shared to some degree by both approved GA drugs. Complement pathway suppression may alter the balance of angiogenic regulation in the retina. Patients receiving IZERVAY should be monitored for signs of wet AMD conversion: visual distortions, straight lines appearing bent, or new deterioration in central vision.

    Key contraindications and precautions for IZERVAY Do not use IZERVAY in patients with: Active ocular or periocular infection; Active intraocular inflammation; History of or active choroidal neovascularization (wet AMD). Monitor for and counsel patients to report: Redness, pain, increased discomfort, worsening redness, or decreased/blurred vision after injection, which may be signs of endophthalmitis or retinal detachment; Visual distortions or new central vision changes, which may be signs of wet AMD conversion; Flashes of light or increased floaters, which may be signs of possible retinal complications. Patients should not drive or use machinery until vision has recovered after each injection. Full prescribing information is available at accessdata.fda.gov.

    What Removing the 12-Month Cap Means in Practice

    The original IZERVAY approval in August 2023 included a duration limitation: the label authorized use for up to 12 months. This ceiling was not arbitrary. It reflected the controlled trial data available at the time of the initial BLA, which covered only year-one efficacy and safety from GATHER2.

    Following a regulatory path that included a supplemental NDA submission, an initial Complete Response Letter from the FDA in November 2024, a rapid resubmission in December 2024, and FDA approval on February 13, 2025, the label no longer carries that limitation.

    Before (original label)After (updated label, Feb 2025)
    Duration of treatment limited to 12 monthsNo limitation on duration of treatment
    Patients approaching the 12-month mark faced uncertainty about continuationOngoing treatment can continue without an administrative ceiling
    Physicians managing longer-term patients had limited label supportFull prescribing information now covers two years of documented efficacy and safety
    Every-other-month dosing option in year 2 not formally labeledGATHER2 year-2 EOM data incorporated; flexible dosing schedules now supported by label

    The label change also has implications for the roughly 210,000 vials of IZERVAY distributed through December 2024. Patients already on therapy who were managed month-to-month under the year-one framework can now continue with the support of two-year efficacy and safety data in the formal prescribing information.

    Post-marketing safety reporting through the time of the label update remained consistent with the clinical trial program. No new or significant safety signals were identified in commercial use.

    IZERVAY in Context: Two Approved Drugs for a Disease Once Left Untreated

    The GA treatment landscape currently consists of two FDA-approved intravitreal complement inhibitors. No head-to-head clinical trial comparing them has been conducted. Here is a plain-language comparison of where they stand:

    FeatureIZERVAY (avacincaptad pegol)Syfovre (pegcetacoplan)
    DeveloperAstellas PharmaApellis Pharmaceuticals
    MechanismComplement C5 inhibitor (RNA aptamer)Complement C3 inhibitor (pegylated peptide)
    Original FDA approvalAugust 2023February 2023
    Duration restrictionNone, removed Feb 2025None
    DosingMonthly or every other month (EOM)Monthly or every other month (EOM)
    Pivotal trial primary endpoint (yr 1)GATHER1: 27% reduction (2 mg); GATHER2: 14% reductionOAKS: 21% reduction (monthly); DERBY: 12% reduction (not statistically significant)
    Statistically significant primary endpointMet in both Phase 3 trials (GATHER1 and GATHER2)Met in OAKS; not met in DERBY
    Post-marketing retinal vasculitis signalNot observed in clinical trialsRare cases reported in post-marketing surveillance
    Intraocular inflammationNo serious cases in GATHER2 through 2 yearsReported in post-marketing; retinal vasculitis cases
    EU regulatory statusEMA application withdrawn by Astellas (Oct 2024)Refused marketing authorization by EMA (Sep 2024)
    Patient population studiedNon-center-point-involving GA onlyBoth subfoveal and non-subfoveal GA (broader population)

    A few contextual points are worth understanding:

    Neither drug has demonstrated improvement in best-corrected visual acuity (BCVA) in their pivotal trials, which is a genuine limitation and the source of ongoing debate in the retinal community. The EMA declined to approve both drugs on the grounds that lesion slowing without demonstrated functional benefit did not meet the European standard for clinical meaningfulness. The FDA, evaluating the same data, reached a different conclusion, accepting lesion growth rate as a valid surrogate endpoint for GA progression.

    IZERVAY’s pivotal trials enrolled patients with non-center-point-involving GA, meaning GA that had not yet reached the central fovea. Syfovre’s trials enrolled a broader population including patients with subfoveal GA. This enrollment difference means the two trials are not directly comparable, and patients with subfoveal involvement are outside the population studied in GATHER1 and GATHER2.

    No randomized head-to-head comparison has been conducted. The right drug for an individual patient involves shared decision-making with a retinal specialist considering both efficacy and safety, individual risk factors, and payer formulary.

    Both drugs require indefinite monthly or bimonthly intravitreal injections, a significant treatment burden for an older patient population, many of whom have bilateral GA.

    What This Means for Patients with Geographic Atrophy

    The removal of the 12-month dosing limit is straightforward good news for patients already on IZERVAY who are tolerating the drug and want to continue. It is also good news for prescribers who can now manage GA patients on a longer-term basis with full label support and two years of documented efficacy and safety data.

    What this approval does not change is the fundamental nature of GA treatment: these drugs slow the progression of an irreversible disease. They do not restore lost vision. The decision to start, continue, or stop treatment involves weighing modest lesion-growth benefit against the burden of indefinite injections, the small risk of wet AMD conversion, and the individual patient’s preferences, disease location, and visual function goals.

    For patients with GA who have not yet been treated, the conversation with a retinal specialist should now include the full picture of two-year data, the flexibility of monthly or every-other-month dosing, and the comparative safety and efficacy profiles of the two available treatments.

    The American Academy of Ophthalmology and the BrightFocus Foundation maintain current patient resources on geographic atrophy and AMD treatment options. For patients interested in clinical trials evaluating next-generation GA therapies, ClinicalTrials.gov lists open enrollment studies.

    For related coverage of how FDA label updates are expanding treatment options across multiple specialties in 2026, see our post on Nexplanon’s FDA-approved extension from 3 years to 5 years and our analysis of the first approved immunotherapy for ovarian cancer.

    Sources

    Astellas press release: U.S. FDA Approves Expanded Label for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy. February 13, 2025. newsroom.astellas.com.

    GATHER2 two-year results: Khanani AM et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial. Ophthalmology. Published online December 15, 2025. doi:10.1016/S0161-6420(25)00790-0

    GATHER1 Phase 2/3 results: Jaffe GJ et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial (GATHER1). Ophthalmology. 2021;128(4):576–586.

    GATHER2 12-month results: Khanani AM et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. The Lancet. September 2023.

    GATHER2 trial registration: NCT04435366. ClinicalTrials.gov.

    GATHER1 trial registration: NCT02686658. ClinicalTrials.gov.

    IZERVAY original FDA approval: FDA approves avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration. FDA.gov. August 2023.

    IZERVAY prescribing information: IZERVAY (avacincaptad pegol intravitreal solution). FDA.gov.

    Ophthalmology Advisor label update coverage: Izervay Label Update Removes Limit on Treatment Duration for Geographic Atrophy. ophthalmologyadvisor.com. February 2025.

    Applied Clinical Trials: Two Year Trial Data Show Long-Term Efficacy of Izervay. appliedclinicaltrialsonline.com.

    AAO IZERVAY/Syfovre overview: What to Know About Syfovre and Izervay for Geographic Atrophy. aao.org. April 2025.

    EMA Syfovre refusal: Syfovre: Final opinion confirming refusal of marketing authorisation. EMA. September 2024.

    FDA Syfovre retinal vasculitis safety communication: FDA Drug Safety Communication: FDA warns about rare but serious risk of vision loss from retinal vasculitis associated with Syfovre. FDA.gov.

    Patient resources: American Academy of Ophthalmology | BrightFocus Foundation | NEI AMD overview | ClinicalTrials.gov: geographic atrophy studies

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions regarding IZERVAY or any other geographic atrophy therapy should be made in consultation with a qualified, board-certified ophthalmologist or retinal specialist who can evaluate individual disease characteristics, risk factors, and treatment goals.
  • The First Gene Therapy for Deafness Is Here and It’s Free. Here’s What That Actually Means.

    The First Gene Therapy for Deafness Is Here and It’s Free. Here’s What That Actually Means.

    📌 The essentials On April 23, 2026, the FDA approved Otarmeni (lunsotogene parvec-cwha, Regeneron) as the first FDA-approved gene therapy for inherited deafness in history. The therapy is indicated for children and adults with profound hearing loss due to biallelic mutations in the OTOF gene, which causes a condition where the inner ear is structurally normal but cannot transmit sound signals to the brain. The clinical basis: Results from the CHORD Phase 1/2 trial (NCT05295056) showing 80% of participants (16 of 20) achieved or exceeded the primary endpoint at 6 months, and 42% of participants with longer follow-up achieved normal hearing. Nine of 12 children who received the therapy gained enough hearing to stop using cochlear implants. The approval was granted under accelerated approval with continued approval contingent on confirmatory trial results. This was also the first gene therapy approved under the FDA’s Commissioner’s National Priority Voucher (CNPV) program, approved in just 61 days after BLA submission. The price: Regeneron has stated it will provide Otarmeni at no cost for the drug itself to eligible patients in the United States. Important caveat: the surgical procedure required to administer it is not covered by Regeneron and will be subject to normal insurance and cost-sharing.

    When Travis Smith was born, he failed his newborn hearing test. His mother, Sierra, was told it was probably just fluid in the ears. But weeks passed, and nothing changed. Slamming pots and pans, yelling his name — nothing reached him. Travis was, as Sierra later described it, 100% deaf.

    A few months later, after genetic testing confirmed a mutation in a gene called OTOF, Travis received an experimental treatment at Columbia University in New York. About ten weeks after the procedure, Sierra laughed loudly while driving. Travis, asleep in his car seat, startled for the first time. She and her friend started yelling. He woke up.

    On April 23, 2026, that experimental treatment became Otarmeni (lunsotogene parvec-cwha), the first FDA-approved gene therapy for inherited deafness in history. And in a move that surprised nearly everyone in the pharmaceutical industry, Regeneron announced it will provide the drug at no cost to eligible patients in the United States.

    There is a lot to unpack here: the science, the price, the very reasonable counterarguments from the Deaf community, and what this means for the larger field of genetic hearing loss.

    What Is OTOF-Related Hearing Loss?

    Hearing happens through a remarkably precise chain of events. Sound waves enter the ear canal, cause the eardrum to vibrate, and those vibrations travel through three tiny bones in the middle ear before reaching the cochlea, the snail-shaped structure of the inner ear. Inside the cochlea, thousands of hair cells convert those vibrations into electrical signals. A protein called otoferlin is what allows those hair cells to release the neurotransmitters that carry those signals to the auditory nerve and then on to the brain.

    In children with biallelic mutations in the OTOF gene, meaning they inherited a non-working copy from both parents, otoferlin is absent or non-functional. The cochlea is structurally intact. The hair cells are there. Sound waves are converted normally. But the signal cannot be passed to the brain because the neurotransmitter release mechanism is broken. The result is profound sensorineural deafness from birth, despite an otherwise normal-looking inner ear.

    OTOF mutations account for roughly 2% to 8% of inherited non-syndromic hearing loss, according to the FDA. In absolute numbers, about 50 babies are born each year in the United States with the condition, a number small enough that most audiologists and pediatricians will rarely encounter it. But the impact on those families is total..

    How Otarmeni Works

    Otarmeni is an adeno-associated virus (AAV) vector-based gene therapy, specifically a dual-vector system, because the OTOF gene is unusually large and too big to fit inside a single AAV. Regeneron’s approach splits the gene in half across two AAV serotype 1 vectors that are co-administered. Once inside the hair cells, the two halves recombine to produce a functional OTOF gene, which then directs the cells to make working otoferlin protein.

    The treatment is administered surgically. Under general anesthesia, a surgeon makes a small incision behind the ear to access the cochlea and delivers the viral vectors directly into the fluid-filled space of the inner ear via a syringe and catheter, a procedure similar in approach to cochlear implant surgery, though the anatomy targeted is slightly different. The therapy can be given to one ear or both.

    One important technical detail: the OTOF gene in Otarmeni is under the control of a proprietary Myo15 promoter, which is designed to restrict gene expression specifically to hair cells that normally produce otoferlin. This cell-type specificity is important both for efficacy and safety, as it reduces the chance of off-target expression in tissues that do not need the protein.

    Why is the OTOF gene so large, and why does that matter? Standard single-AAV gene therapies are limited by the packaging capacity of the virus, roughly 4.7 kilobases of genetic material. The OTOF gene is approximately 6 kilobases, which has long made it technically challenging to deliver in a single vector. Regeneron’s dual-AAV approach is one of several strategies the field has developed to work around this constraint. It addresses the same large-gene delivery challenge that has been encountered in gene therapy for conditions like Duchenne muscular dystrophy. The fact that this approach produced consistent, durable results in the CHORD trial is a meaningful technical achievement, not just for hearing loss, but for the broader field of large-gene delivery.

    The CHORD Trial: What the Clinical Data Shows

    The FDA approval is based on results from the CHORD trial (NCT05295056), an ongoing, registrational Phase 1/2 multicenter, open-label study. Twenty participants aged 10 months to 16 years with molecularly confirmed OTOF mutations received a single dose of Otarmeni in one or both ears. The primary endpoint was improvement in hearing sensitivity measured by pure-tone audiometry at week 24.

    CHORD trial key results
    Participants meeting or exceeding primary endpoint at 6 months16 of 20 (80%)
    Participants achieving normal hearing with longer follow-up42%
    Children who stopped using cochlear implants after treatment9 of 12
    Minimum follow-up with durable hearing benefitsAt least 2 years
    Age range in trial10 months to 16 years
    Effect of age at treatment on efficacyNot significant, which supported label inclusion of adults
    Most common adverse eventsMiddle ear infection or inflammation, vomiting, nausea, dizziness (consistent with surgical procedure)

    Source: CHORD Phase 1/2 trial, NCT05295056. Primary results published in NEJM, 2026.

    Accelerated approval: what it means here Otarmeni received accelerated approval based on improvement in pure-tone audiometry as a surrogate endpoint. Continued approval may be contingent upon verification of treatment effects on clinical measures of speech development and quality of life, the outcomes families ultimately care most about. The confirmatory portion of the CHORD trial is ongoing. The FDA specifically notes that durability of hearing improvement is a key variable still being assessed. For a one-time gene therapy, how long the benefit lasts is the central question that will define long-term clinical value and public health cost-effectiveness. The approval was also notably fast: granted just 61 days after the Biologics License Application was filed, tied for the fastest BLA approval in modern FDA history, and the first gene therapy approved under the FDA’s Commissioner’s National Priority Voucher (CNPV) program. For context on how the CNPV program works and which other drug programs have received vouchers, see our post on the FDA’s fast-tracking of three psychedelic drug programs.

    The Price Tag: $0. What Is Actually Going On There?

    Gene therapies for rare diseases are expensive. Not slightly expensive — the kind of expensive that regularly makes headlines. Hemgenix (hemophilia B) was priced at $3.5 million per patient. Zolgensma (spinal muscular atrophy) at $2.1 million. Casgevy (sickle cell disease) at $2.2 million. These prices reflect the reality of developing treatments for patient populations sometimes numbering in the hundreds, where there is no scale to amortize development costs.

    Regeneron’s internal analysis suggested Otarmeni could have been priced as high as $4 million per patient, generating an estimated $200 million to $400 million in annual revenue. The company chose not to. Regeneron’s co-founder and president, Dr. George Yancopoulos, acknowledged the company made a deliberate choice to prioritize access over revenue from this particular therapy, despite internal discussion about alternative pricing models.

    That decision came alongside Regeneron’s participation in the Trump administration’s Most Favored Nation drug pricing announcement, a policy effort to bring U.S. drug prices more in line with prices paid in European and Asian markets. The timing was politically convenient, but the substance of offering the therapy free stands regardless of the surrounding context.

    Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER), noted in a statement following the approval that Regeneron has shown that one option companies can consider to ensure affordable patient access to these therapies is to simply not charge the health system for the drug. She called it a model worth understanding for what it demonstrates about the range of approaches available to developers of rare disease therapies.

    There are important nuances in the “free” framing worth noting clearly. Regeneron is providing the drug itself at no cost to clinically eligible patients. The company does not control and is not covering the cost of the surgical procedure required to administer it. Cochlear implant surgery, which uses a similar approach, typically costs between $30,000 and $100,000 including hospitalization and anesthesia. The out-of-pocket portion for patients will depend on their insurance coverage for the procedure, not the drug.

    Otarmeni’s pricing model also has no established precedent for international markets. CEO Leonard Schleifer told CNBC that overseas pricing has not been set, stating that other countries should pay their fair share. For families outside the United States with children who have OTOF mutations, the picture is much less clear.

    A Perspective Worth Sitting With: The Deaf Community Response

    Not everyone greeted this approval with unqualified celebration, and that response deserves more than a footnote.

    Jaipreet Virdi, a historian of medicine, technology, and deafness at the University of Victoria who is herself deaf, raised a concern that has been articulated within Deaf culture for years: that genetic therapies targeting deafness can reinforce the assumption that deafness is a deficiency to be corrected rather than a difference to be accommodated. For members of the Deaf community who use sign language, have Deaf cultural identities, and live full, rich lives, a medical framing of deafness as a problem in need of eradication is not a neutral position.

    This is not a fringe view. It is a well-established strand of Deaf cultural identity that preceded cochlear implants and will continue to evolve as genetic therapies expand. It does not invalidate what Otarmeni has done for Travis, or Miles, or the other children in the CHORD trial. But it does mean that the conversation around who benefits from these therapies, and on what terms, is more complex than the headline numbers suggest.

    Regeneron’s own press release acknowledged this directly. Janet DesGeorges, Executive Director of Hands and Voices, a family-driven organization supporting children with all forms of hearing loss and all communication approaches, was quoted in the approval announcement noting that families deserve access to balanced information and a range of options when navigating genetic hearing loss, and that the choice of approach belongs to individual families.

    Cochlear implants versus gene therapy: how they are different Cochlear implants are electronic devices surgically implanted in the inner ear that bypass damaged hair cells and directly stimulate the auditory nerve. They restore useful hearing for many patients but do not restore physiological hearing. The sound quality is different from natural hearing and varies considerably between users. They require external processors worn behind the ear, run on batteries, and must be managed over a lifetime. Otarmeni, by contrast, restores the biological mechanism of hearing by enabling the hair cells themselves to function. The hearing it produces is closer to natural hearing that is present continuously without external hardware. However, it only works for patients with OTOF mutations who have no prior cochlear implant in the ear to be treated. The two approaches are not directly comparable and serve partially overlapping but distinct populations.

    Beyond OTOF: What This Approval Unlocks

    OTOF mutations account for only 1% to 3% of cases of genetic hearing loss at birth. The significance of this approval is therefore less about its immediate patient population, roughly 50 children per year in the U.S., and more about what it proves and where it leads.

    Genetic hearing loss involves more than 100 identified genes. OTOF attracted early attention because its mechanism was well-understood, the hair cell pathology is isolated (outer hair cell function is preserved), and the AAV delivery route to the cochlea had been mapped in preclinical models. Proving that this approach works, that you can deliver a gene to inner ear hair cells via surgical infusion and produce durable, functional hearing, is the foundational result the broader field needed.

    Eli Lilly and several academic groups are also developing gene therapies targeting OTOF, many showing comparably strong results. The publication of strong data in the New England Journal of Medicine in 2026, which preceded and contributed to the FDA’s accelerated review, has drawn significant investment into the broader genetic hearing loss space. Dr. Lawrence Lustig of Columbia University, who treated several CHORD participants, noted substantial interest in pursuing other forms of genetic deafness that are more common, and that investment is now arriving.

    Researchers are also beginning to consider whether someday gene therapy approaches might address acquired hearing loss from aging or noise exposure, which affects hundreds of millions of people globally. That is a much longer road, requiring different targets and delivery methods. But the clinical validation of cochlear gene delivery in OTOF patients makes it a more credibly walkable path than it was before April 23, 2026.

    What This Approval Does Not Yet Answer

    How long does the benefit last?

    The CHORD trial has follow-up of at least two years in some participants, and hearing benefits have been durable over that period. But two years is a short window for what is being offered as a one-time, potentially permanent treatment, particularly for children who may live for seven more decades. Long-term follow-up from the confirmatory CHORD trial will be critical. The FDA has specifically listed durability of hearing improvement as a condition of continued approval.

    What about speech and language development?

    Pure-tone audiometry tells us whether a patient can detect sounds at various frequencies and volumes. It does not directly measure what matters most to families: speech comprehension, language acquisition, and the ability to communicate in the ways they choose. The confirmatory trial is tasked with verifying treatment effects on these clinical measures. The gap between “can detect a whisper” and “is developing speech and language normally” is the one families and clinicians most need filled.

    Which patients are candidates?

    The indication requires molecularly confirmed biallelic OTOF variants, preserved outer hair cell function (confirmed by otoacoustic emissions testing), and no prior cochlear implant in the ear to be treated. Genetic testing infrastructure for identifying OTOF mutations in newborns varies considerably across health systems. The therapy’s real-world reach will depend partly on how systematically genetic diagnosis of congenital deafness is pursued, which is currently inconsistent in the U.S.

    For families navigating genetic hearing loss:

    This approval touches on intersecting questions: the science of gene delivery, the ethics of treating deafness, the unprecedented pricing decision, and what proof-of-concept in OTOF means for the dozens of other genetic causes of hearing loss. For families with children recently diagnosed with genetic hearing loss, regardless of which gene is involved, several organizations maintain current resources:

    Hands and Voices supports families navigating all communication approaches without advocacy for any single one. The National Association of the Deaf (NAD) provides resources from a Deaf cultural perspective. The Hearing Loss Association of America (HLAA) offers advocacy and practical support resources. The NIDCD maintains clinical information on cochlear implants and emerging therapies. Families interested in the CHORD confirmatory trial or other OTOF gene therapy studies can search for open enrollment studies at ClinicalTrials.gov.

    Sources

    FDA approval announcement: FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program. FDA.gov. April 23, 2026.

    Regeneron press release: Otarmeni (lunsotogene parvec-cwha) Approved by FDA. investor.regeneron.com. April 23, 2026.

    CHORD trial registration: NCT05295056. ClinicalTrials.gov.

    Primary clinical data: CHORD Phase 1/2 trial results. New England Journal of Medicine. 2026.

    ICER pricing commentary: Institute for Clinical and Economic Review. Statement on Otarmeni pricing. icer.org.

    Pricing context (CNBC): Schleifer L. Regeneron weighs overseas price for Otarmeni. CNBC. April 24, 2026.

    Deaf community perspective: Virdi J. Quoted in NPR/KERA News. Rob Stein. The FDA gives the green light to the first gene therapy for deafness. keranews.org. April 23, 2026.

    Hands and Voices: handsandvoices.org. Cited in Regeneron approval press release.

    Patient story (Travis): NPR/KERA News. Rob Stein. April 23, 2026.

    Patient story (Miles): CNN. Meg Tirrell. April 23, 2026.

    Pipeline context: Gene therapy for deafness approved. Science. April 23, 2026.

    Patient and family resources: Hands and Voices | National Association of the Deaf | Hearing Loss Association of America | NIDCD Cochlear Implants | ClinicalTrials.gov: OTOF hearing loss

    Disclaimer: Health Evidence Digest provides general information about health research and FDA decisions for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Accelerated approval does not constitute final confirmation of clinical benefit. The confirmatory CHORD trial is ongoing. Always consult a qualified audiologist, otolaryngologist, or geneticist regarding treatment decisions for your child or yourself.
  • Hands. Grip. Independence. What the FDA’s Clearance of the ExaStim® System Actually Means for Spinal Cord Injury Rehab.

    Hands. Grip. Independence. What the FDA’s Clearance of the ExaStim® System Actually Means for Spinal Cord Injury Rehab.

    📌 The essentials On April 16, 2026, the FDA cleared the ExaStim Stimulation System (ANEUVO) for use in the United States, marking the first FDA-cleared transcutaneous spinal cord stimulation device for home use in adults with incomplete spinal cord injury. Important terminology: this is an FDA 510(k) clearance, not a drug approval. The distinction matters and is explained below. What ExaStim is cleared for: improving hand sensation and strength in adults aged 18 to 75 with chronic, non-progressive neurological deficits resulting from incomplete spinal cord injury, when used in conjunction with functional task practice. Where it can be used: both clinical settings and at home, under a prescribing clinician’s supervision. The regulatory basis: ExaStim received FDA Breakthrough Device Designation, completed the ASPIRE clinical study at the Kennedy Krieger Institute and other sites, and received CE Mark certification in Europe in April 2025 before U.S. clearance. The broader context: ExaStim is entering a real but still-developing evidence base for transcutaneous spinal cord stimulation. What the clinical data shows, where it is strongest, and where legitimate gaps remain is what this post covers.

    Spinal cord injury (SCI) affects approximately 18,000 Americans each year and an estimated 302,000 people currently live with SCI in the United States. The consequences are not uniform. About 69% of new SCI cases are classified as incomplete, meaning some neural pathways across the injury site are preserved, and some degree of function below the level of injury remains possible. For people with cervical incomplete SCI specifically, the loss of hand and arm function is consistently ranked as the highest priority for recovery, above walking. Being able to hold a cup. Press a button. Open a door independently. These are not small things.

    The standard rehabilitation toolkit for incomplete SCI, including physical therapy, occupational therapy, and conventional functional electrical stimulation, produces meaningful but limited gains for many patients. A growing body of research has been investigating whether non-invasive electrical stimulation of the spinal cord itself, delivered through electrodes placed on the skin rather than surgically implanted, can amplify the nervous system’s own residual capacity for recovery.

    The FDA’s April 16 clearance of the ExaStim Stimulation System from ANEUVO represents the first time a transcutaneous spinal cord stimulation device has been cleared specifically for at-home use in incomplete SCI in the United States. This post covers what the device is, how it works, what the clinical evidence actually shows about transcutaneous spinal stimulation as a treatment class, what the ASPIRE study contributed, and what this clearance does and does not mean for patients navigating SCI rehabilitation.

    What Is Transcutaneous Spinal Cord Stimulation and Why Is It Relevant to SCI?

    To understand what ExaStim does, it helps to understand what happens at the neuromuscular level in incomplete spinal cord injury and why spinal stimulation might influence it.

    The injured spinal cord is not simply broken

    In a complete SCI, the neural pathways crossing the injury site are entirely severed, and no voluntary signal from the brain reaches muscles below the injury. In an incomplete SCI, some pathways remain partially intact. But “partially intact” does not mean “working normally.” The surviving connections often cannot generate sufficient neural drive on their own to produce coordinated voluntary movement. The circuits exist, but they are not generating enough signal to translate into function.

    Neuroplasticity, the nervous system’s capacity to reorganize and strengthen connections through activity-based learning, is a central principle of SCI rehabilitation. The more consistently neural circuits are activated, the more the nervous system can reinforce and strengthen those connections over time. This is why task-specific training, where you practice the actual functional movement you are trying to recover, tends to outperform generalized exercise in SCI rehabilitation.

    Transcutaneous spinal cord stimulation (tSCS) delivers low-level electrical current through electrodes placed on the skin over the spinal cord, at the level corresponding to the neural circuits being targeted. For upper extremity function in cervical SCI, electrodes are typically placed at the cervical spinal level, approximately C4 to C7. The proposed mechanism is that tSCS increases the excitability of surviving neural pathways and the motor neuron pools they connect to, making it easier for the brain’s residual descending signals to produce muscle activity. In effect, it lowers the threshold for the injured circuits to fire, potentially unlocking function that exists but cannot be accessed without facilitation.

    What distinguishes ExaStim within the tSCS category

    ExaStim uses a multi-electrode array rather than the single-pair electrode configurations used in earlier-generation tSCS research. This matters because different muscle groups in the arm and hand are controlled by different spinal cord segments and fiber pathways. A multi-electrode system allows the stimulation to be spatially targeted and the parameters personalized to an individual patient’s injury level, neurological profile, and therapy goals, rather than delivering a single undifferentiated current across the whole area. The system is controlled via a mobile digital device, enabling flexible parameter adjustment in clinical and home settings.

    ExaStim received FDA Breakthrough Device Designation, a designation reserved for devices that provide more effective treatment or diagnosis of a serious condition compared to available options and where no approved alternative exists. This designation preceded the FDA clearance and provided an expedited review pathway.

    The Regulatory Distinction: Clearance Versus Approval

    The original post on this site described ExaStim as “approved,” which is not technically accurate and is worth correcting explicitly. This distinction matters on a health evidence site.

    FDA clearance (510(k)) means the FDA has determined that a device is substantially equivalent to a legally marketed predicate device in terms of its intended use and technological characteristics. It is the standard pathway for medical devices. The clearance process does not require the same level of randomized controlled trial evidence as a drug approval. It requires demonstration of safety and effectiveness sufficient to establish substantial equivalence.

    FDA approval (PMA or BLA) is the more rigorous pathway used for higher-risk devices or drugs, requiring independent demonstration of safety and effectiveness through controlled clinical trials.

    ExaStim was cleared through the 510(k) pathway. This is normal and appropriate for this category of device. It does not mean the device lacks evidence. It means the evidence standard is different from what would be required for a drug approval. The distinction is important for patients and clinicians evaluating the strength of the regulatory basis.

    What the Evidence Shows: The Broader tSCS Literature

    ExaStim’s clearance builds on a growing but still-developing body of research on transcutaneous spinal cord stimulation for SCI. The most important thing to understand about this evidence base is where it is genuinely strong and where gaps remain.

    What the peer-reviewed literature shows

    A 2024 meta-analysis published in Neurorehabilitation and Neural Repair pooled results from six randomized controlled trials of transcutaneous spinal cord stimulation in SCI patients. The analysis found that tSCS combined with conventional rehabilitation significantly improved limb strength (mean difference 4.82, p=0.004) and reduced spasticity (MD 0.40, p=0.02) compared to conventional rehabilitation alone. Walking speed and distance also improved significantly. The upper-extremity motor function composite endpoint did not reach statistical significance in this specific pooled analysis (p=0.75), though individual studies have shown gains in grip strength and hand function.

    A 2024 review published in the Journal of Neurotrauma examining transcutaneous stimulation specifically for upper extremity function in cervical SCI reviewed studies involving 55 participants across multiple research groups. The review found that tSCS combined with task-specific training “consistently improved voluntary control of arm and hand function and sensation,” though noting the studies were limited in number and sample size.

    A 2026 systematic review in Life covering cervical spinal cord stimulation through July 2025, including epidural, intraspinal, and transcutaneous approaches, synthesized preclinical and clinical evidence and found consistent evidence of functional improvement across approaches, while noting substantial heterogeneity across study designs that precluded meta-analysis of the combined dataset.

    A systematic review in PMC covering electrical stimulation modalities for motor recovery in SCI synthesized 37 clinical trials and found consistent evidence of functional improvement, with transcutaneous approaches showing promise as a non-invasive alternative to epidural stimulation.

    What the evidence supports and what it does not yet confirm The evidence for transcutaneous spinal cord stimulation in incomplete SCI supports the following conclusions: tSCS combined with task-specific training improves motor neuron excitability and can augment voluntary movement in incomplete SCI. Limb strength and spasticity improvements are the most consistently demonstrated outcomes across RCTs. Hand and upper extremity function improvements have been shown in multiple studies, though the evidence base here is smaller and more heterogeneous than for lower extremity outcomes. The technology is safe and well-tolerated based on available data, with no major safety signals identified across the clinical trial literature. What the evidence does not yet confirm: long-term durability of functional gains after treatment ends, optimal stimulation parameters (frequency, intensity, electrode placement) for different injury levels and patient profiles, whether benefits generalize across the full spectrum of incomplete SCI severity, and how ExaStim’s specific multi-electrode platform compares to single-electrode systems used in most published research. These are legitimate open questions that the post-clearance clinical data and the ASPIRE long-term follow-up will need to address.

    The ASPIRE Study: ANEUVO’s Foundational Clinical Evidence

    The ASPIRE (Assessing non-invasive spinal Stimulation and PT/OT for motor Improvement Response with ExaStim) study was ANEUVO’s registrational clinical program, conducted at the International Center for Spinal Cord Injury at Kennedy Krieger Institute, affiliated with Johns Hopkins University School of Medicine, and at additional sites across the United States.

    The study enrolled adults with upper extremity paralysis due to chronic, traumatic incomplete SCI. Participants received ExaStim tSCS therapy in combination with traditional physical and occupational therapy (PT/OT) rehabilitation as an adjunct treatment. The FDA designated the study as non-significant risk (NSR), meaning the agency determined that the risk profile did not warrant the oversight requirements applied to significant-risk device studies.

    ANEUVO completed the ASPIRE study and has stated that results will be shared in early 2026. The full peer-reviewed publication of ASPIRE data has not yet been publicly available at the time of this post. The clearance was supported by the ASPIRE dataset alongside the preceding pilot study and the broader tSCS literature.

    The pilot study that preceded ASPIRE, published in the Archives of Physical Medicine and Rehabilitation in 2023, evaluated ExaStim in a small group of participants with incomplete SCI and found preliminary evidence of treatment safety and possible effectiveness in improving upper limb function. The authors, who included both ANEUVO employees and independently funded investigators, noted that further investigation in a larger trial was warranted, which the ASPIRE study was designed to provide.

    Important disclosure context: Several investigators in the ExaStim research program, including the ASPIRE principal investigator Dr. Rebecca Martin and others, received research funding from ANEUVO. Dr. Yi-Kai Lo and Rachel Yung are ANEUVO employees. This does not invalidate the research, but it is relevant context for interpreting company-funded data pending independent replication.

    What FDA Clearance for Home Use Means in Practice

    The clearance of ExaStim for both clinical and at-home use is notable. Most rehabilitation neurostimulation devices are limited to clinical or supervised settings. ExaStim’s home-use clearance means that once prescribed by a clinician, patients can continue therapy in their own home environment, extending the treatment dose beyond what clinic visits alone allow.

    This matters because neuroplasticity-based rehabilitation for SCI appears to be dose-dependent: more frequent, consistent activation of the target neural circuits tends to produce better outcomes. Clinic-only therapy typically means two to three sessions per week. Home use could mean daily therapy, compressing the treatment timeline and potentially improving outcomes.

    The practical requirements for home use include:

    • The device must be prescribed by a qualified clinician
    • Initial setup, parameter programming, and training occur in a clinical setting
    • Patients must be trained on electrode placement, device operation, and recognition of adverse effects
    • Ongoing clinical oversight continues throughout the home therapy period
    • The therapy is used in conjunction with functional task practice, not as a standalone intervention

    The home-use clearance also has implications for access. Clinic-based rehabilitation is limited by geography, transportation, and appointment availability. For patients in rural or underserved areas, a home-based tSCS system potentially removes a significant logistical barrier to consistent rehabilitation. Whether insurance coverage follows the clearance is a separate and clinically important question. Home medical device coverage under Medicare, Medicaid, and private insurance for novel neuromodulation systems varies and requires prior authorization. Clinicians prescribing ExaStim should be prepared to support patients through the coverage determination process.

    Where ExaStim Fits in the SCI Rehabilitation Landscape

    Spinal cord injury rehabilitation encompasses a wide range of interventions. Here is where transcutaneous spinal cord stimulation, and ExaStim specifically, sits relative to other approaches:

    ApproachHow it worksFDA statusEvidence level
    Physical and occupational therapyTask-specific training, strength, and functionStandard of care, no device clearance neededStrong; foundational
    Functional electrical stimulation (FES)Stimulates peripheral nerves/muscles directly to produce movementMultiple FDA-cleared devices existEstablished; strongest for lower extremity
    Epidural spinal cord stimulationSurgically implanted electrodes deliver continuous or patterned stimulation to dorsal spinal cordFDA cleared/approved for pain; investigational for SCI motor functionGrowing; invasive
    Transcutaneous spinal cord stimulation (tSCS)Non-invasive surface electrodes deliver stimulation to spinal cordExaStim now FDA-cleared for incomplete SCI upper extremityEmerging; consistent signals, limited large RCTs
    Robotic exoskeletonsMechanically assisted movement trainingMultiple FDA-cleared devicesEstablished for gait training

    ExaStim is positioned as an adjunct to, not a replacement for, physical and occupational therapy. The clearance language requires its use “in conjunction with functional task practice,” which is consistent with how tSCS has been used across the clinical trial literature and with the neuroplasticity rationale for the therapy.

    What This Means for Patients and Clinicians

    For patients with incomplete cervical SCI and their families

    The ExaStim clearance represents a genuine expansion of the non-invasive rehabilitation toolkit. The device is the first of its kind cleared for home use in the United States, and the clinical evidence for tSCS as a class supports cautious optimism for upper extremity functional gains when combined with task-specific therapy.

    What to realistically expect: ExaStim is a rehabilitation adjunct. It is designed to improve outcomes when used alongside physical and occupational therapy, not to produce dramatic recovery on its own. The evidence base shows meaningful improvements in grip strength and upper extremity function in incomplete SCI patients, with a good safety profile. The magnitude and durability of individual outcomes will vary.

    What to discuss with your rehabilitation team: whether the degree of incompleteness and level of your injury makes you a candidate for upper extremity tSCS therapy; how ExaStim compares to other FES and neurostimulation devices your team has experience with; what the coverage situation is for your specific insurance; and how home-based ExaStim therapy would be integrated with your current PT/OT program.

    The Christopher and Dana Reeve Foundation and the United Spinal Association both maintain current, clinician-reviewed resources on rehabilitation options for SCI. The Model Systems Knowledge Translation Center at the University of Washington maintains evidence-based SCI rehabilitation guides for patients and families. Clinical trials evaluating transcutaneous spinal cord stimulation can be found at ClinicalTrials.gov.

    For rehabilitation clinicians

    ExaStim’s clearance for home use creates a new prescribing and follow-up responsibility. The device integrates with a mobile platform for parameter management. ANEUVO is building out its clinical partnership program, and training and onboarding support is available through the company. Given that the ASPIRE full dataset has not yet been peer-reviewed and published, clinicians should follow the literature for independent replication of the company-funded results as they become available.

    The tSCS class as a whole has a favorable safety profile across the published literature. The main clinical considerations for patient selection are injury completeness level (incomplete is required; complete injury is outside the cleared indication), chronicity of injury, and upper extremity functional baseline. Patients with implanted electronic devices (pacemakers, deep brain stimulators) are generally not candidates for transcutaneous spinal stimulation.

    Sources

    ANEUVO FDA clearance press release: ANEUVO Receives FDA Clearance for ExaStim Stimulation System. GlobeNewswire. April 16, 2026.

    ASPIRE clinical study registration: NCT05294237. ClinicalTrials.gov.

    ExaStim pilot study: Lo YK et al. A Pilot Study Using ExaStim to Restore Upper Limb Function After Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation. 2023.

    2024 tSCS meta-analysis: Shi C et al. Transcutaneous spinal cord stimulation on motor function in patients with spinal cord injury: A meta-analysis. Neurorehabilitation and Neural Repair. 2024.

    2024 cervical SCI upper extremity review: Singh G et al. Spinal Cord Transcutaneous Stimulation in Cervical Spinal Cord Injury: A Review Examining Upper Extremity Neuromotor Control, Recovery Mechanisms, and Future Directions. Journal of Neurotrauma. 2024.

    2026 systematic review cervical SCS: Cervical Spinal Cord Stimulation for Functional Rehabilitation After Spinal Cord Injury: A Systematic Review. Life. 2026;16(1):179.

    Electrical stimulation systematic review (PMC): Electrical Stimulation and Motor Function Rehabilitation in Spinal Cord Injury: A Systematic Review. PMC11214755.

    SCI statistics: National Spinal Cord Injury Statistical Center. Facts and Figures 2023.

    FDA 510(k) clearance explained: Premarket Notification 510(k). FDA.gov.

    FDA Breakthrough Device Designation: Breakthrough Device Program. FDA.gov.

    Patient resources: Christopher and Dana Reeve Foundation | United Spinal Association | Model Systems Knowledge Translation Center | ClinicalTrials.gov: SCI transcutaneous stimulation

    Disclaimer: Health Evidence Digest provides general information about FDA clearances and health research for educational purposes. This content is not a substitute for professional medical advice. ExaStim was cleared through the FDA’s 510(k) pathway. Decisions about rehabilitation technology and treatment approaches for spinal cord injury should be made in consultation with a qualified physiatrist, physical therapist, or occupational therapist experienced in SCI rehabilitation.

  • Wegovy HD: The FDA Just Approved a Semaglutide Dose Three Times Stronger Than Before. Here’s What the Data Actually Shows.

    Wegovy HD: The FDA Just Approved a Semaglutide Dose Three Times Stronger Than Before. Here’s What the Data Actually Shows.

    📌 The essentials On March 19, 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg injection, Novo Nordisk) for chronic weight management in adults with obesity (BMI of 30 or higher), or overweight (BMI of 27 or higher) with at least one weight-related condition. This is the highest available dose of injectable semaglutide and the first GLP-1 receptor agonist approved under the Commissioner’s National Priority Voucher (CNPV) program. Prerequisite for use: patients must have tolerated the 2.4 mg Wegovy dose for at least 4 weeks, and additional weight reduction must be clinically indicated. The clinical basis: The STEP UP Phase 3b trial, published in The Lancet Diabetes and Endocrinology in November 2025, showed mean weight loss of 20.7% at 72 weeks with semaglutide 7.2 mg versus 15% with semaglutide 2.4 mg. Approximately 1 in 3 participants lost 25% or more of their body weight. 89% of Wegovy HD participants achieved at least 5% body weight loss versus 38% on placebo. The STEP UP T2D trial in participants with obesity and type 2 diabetes showed mean weight loss of 14.1%. What this approval does not change: Wegovy HD is used alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment. The safety profile is consistent with previously established semaglutide effects, with new attention warranted on altered skin sensation at the higher dose.

    When Wegovy (semaglutide 2.4 mg) was approved in June 2021, it represented a meaningful advance in obesity pharmacotherapy. Producing roughly 15% mean body weight loss in clinical trials, it substantially outperformed prior generations of weight management drugs and drove the GLP-1 wave that has since reshaped both prescribing patterns and public conversation around obesity treatment.

    But 15% average weight loss, while meaningful, still leaves many patients short of the weight reduction needed to achieve their health goals. For someone starting at 250 pounds, 15% is about 37 pounds. For patients with significant obesity-related comorbidities who need to lose 60 or 80 pounds to meaningfully reduce cardiovascular risk, type 2 diabetes progression, or joint disease burden, the 2.4 mg ceiling was a clinical limitation.

    Wegovy HD (semaglutide 7.2 mg), approved March 19, 2026, is Novo Nordisk’s answer to that limitation. It is not a new drug. It is the same semaglutide molecule at a higher dose, with a new clinical program demonstrating that going higher produces meaningfully greater weight loss, with a safety profile consistent with what clinicians and patients already know about semaglutide.

    This post covers what the STEP UP trial actually showed, how to read the numbers carefully, who this approval is for, how it fits into the existing semaglutide landscape, and what the CNPV program means for why this approval moved so quickly.

    Semaglutide: A Brief Recap of the Mechanism and Existing Approvals

    Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a class of drugs that mimic the gut hormone GLP-1. GLP-1 is released after eating and signals the pancreas to produce insulin in a glucose-dependent way, suppresses glucagon, slows gastric emptying, and most relevantly for weight management, signals satiety to the brain through receptors in the hypothalamus and brainstem.

    At pharmacological doses, semaglutide produces a potent and sustained reduction in appetite and caloric intake that goes well beyond what natural GLP-1 signaling achieves. The weight loss is real and clinically meaningful, but it is dose-dependent: higher doses produce more robust GLP-1 receptor engagement and, in the clinical trials conducted so far, greater weight loss.

    The existing semaglutide portfolio in the United States includes:

    ProductDoseRoutePrimary indicationFDA status
    Ozempic0.5 mg, 1 mg, 2 mgWeekly injectionType 2 diabetesApproved 2017
    Rybelsus3 mg, 7 mg, 14 mgDaily oral tabletType 2 diabetesApproved 2019
    Wegovy 2.4 mg2.4 mgWeekly injectionChronic weight managementApproved 2021
    Wegovy oral 25 mg25 mgDaily oral tabletChronic weight managementApproved 2025
    Wegovy HD 7.2 mg7.2 mgWeekly injectionChronic weight managementApproved March 2026

    Wegovy HD joins this portfolio as a step-up option specifically for patients who have been on Wegovy 2.4 mg for at least four weeks and need greater weight reduction. It is not a replacement for the existing 2.4 mg formulation, and it is not the starting point for treatment-naive patients.

    The STEP UP Trials: What the Evidence Actually Shows

    The FDA approval is based on two Phase 3b trials, both published in The Lancet Diabetes and Endocrinology in November 2025.

    STEP UP (obesity without type 2 diabetes)

    The STEP UP trial enrolled approximately 1,400 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition. Participants were randomized to once-weekly semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo, all as adjuncts to lifestyle intervention, over 72 weeks. Mean baseline body weight was approximately 248 pounds (112.5 kg).

    OutcomeSemaglutide 7.2 mgSemaglutide 2.4 mgPlacebo
    Mean body weight loss at 72 weeks20.7%~15%~2 to 3%
    Participants losing 25% or more~1 in 3 (approx. 33%)Substantially lowerRare
    Participants achieving at least 5% weight loss89%Higher than placebo38%
    Statistical significance vs. placeboYes (p less than 0.0001)YesReference
    Statistical significance vs. 2.4 mgYes (superior)Reference—

    Source: Wharton S, Freitas P, Hjelmesaeth J, et al. STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8

    A mean weight loss of 20.7% from a baseline of approximately 248 pounds translates to roughly 51 pounds of average weight reduction. The finding that approximately 1 in 3 participants achieved 25% or greater weight loss is the number generating the most clinical interest, because it suggests that a meaningful subset of patients on the 7.2 mg dose approaches the weight loss territory previously associated only with bariatric surgery.

    For context, Roux-en-Y gastric bypass typically produces 25 to 35% total body weight loss over two years. The overlap between the upper end of pharmacological response with Wegovy HD and surgical outcomes is a genuinely new development in obesity medicine, with implications for how patients and clinicians think about the threshold for surgical consideration.

    STEP UP T2D (obesity with type 2 diabetes)

    The STEP UP T2D trial enrolled approximately 500 adults with obesity and type 2 diabetes. Semaglutide 7.2 mg produced mean weight loss of 14.1% at 72 weeks compared to placebo. The lower magnitude versus the non-diabetes STEP UP trial is consistent with the pattern seen throughout the semaglutide clinical program: type 2 diabetes attenuates GLP-1-mediated weight loss. This is likely because individuals with established T2D have varying degrees of beta cell dysfunction and altered GLP-1 receptor sensitivity that reduces the drug’s weight-lowering effect. The 14.1% figure is still a clinically meaningful weight loss in a T2D population and substantially better than prior generation weight management drugs.

    How to Read the 20.7% Carefully

    The 20.7% mean weight loss headline deserves careful interpretation.

    It is a mean, not a universal outcome. Mean weight loss describes the average across all participants who completed the trial. Some participants lost substantially more. Some lost less, and some may have lost little or nothing. The 1-in-3 statistic for 25% or greater loss and the 89% statistic for at least 5% loss together give a clearer picture of the distribution: the vast majority of participants achieved meaningful weight loss, and a substantial minority achieved very large weight loss.

    72 weeks is not a lifetime. The trial ran for 72 weeks (approximately 17 months). What happens to weight after year two, especially if the drug is discontinued, is a well-established concern across the entire GLP-1 class. Studies of semaglutide 2.4 mg discontinuation show substantial weight regain after stopping treatment. The same pattern should be assumed for Wegovy HD until data proves otherwise. This is a chronic medication for a chronic condition, not a course of treatment with a defined end.

    The comparison to 2.4 mg matters for patient selection. The additional weight loss of approximately 5 to 6 percentage points over the existing Wegovy 2.4 mg dose is real and statistically significant, but it comes with additional cost, potentially greater side effect burden, and the requirement for prior tolerance of the lower dose. For patients at or near their weight management goals on 2.4 mg, the step-up may not be necessary or clinically indicated. The label specifically requires that additional weight reduction be clinically indicated before stepping up.

    Safety: What’s the Same and What’s New at 7.2 mg

    The safety profile of Wegovy HD is broadly consistent with established semaglutide pharmacology. Clinicians and patients familiar with Wegovy 2.4 mg will recognize most of the safety considerations.

    Consistent with prior semaglutide experience:

    New at the higher dose:

    The clinical data from STEP UP identified altered skin sensation, including sensitivity, pain, or burning, at a higher frequency than seen with the 2.4 mg dose. Most cases resolved spontaneously or with dose adjustment, but this is a new signal worth counseling patients about before initiating.

    What the label requires for step-up:

    Patients must have tolerated semaglutide 2.4 mg for at least four weeks before stepping up to 7.2 mg. This requirement reflects both the clinical logic of demonstrating tolerance at the lower dose and the practical need to allow the most common GI side effects to stabilize before adding a higher dose burden.

    The CNPV Connection: Why This Approval Moved Quickly

    Wegovy HD was the first GLP-1 receptor agonist to receive a Commissioner’s National Priority Voucher (CNPV) and, notably, the first product to be approved under the CNPV program (the program was used for Wegovy HD before the subsequent psychedelic drug designations announced in April 2026).

    As covered in our post on the FDA’s fast-tracking of psychedelic drug programs, a CNPV compresses the FDA review timeline to approximately one to two months from NDA submission versus the standard 10 to 12 months. It does not change the evidentiary standard for approval. The drug still needs to demonstrate substantial evidence of safety and efficacy. It means the FDA will prioritize the review and engage more frequently with the sponsor.

    The CNPV for Wegovy HD reflects the FDA’s and the current administration’s positioning of obesity treatment as a national health priority, consistent with the executive orders and policy signals throughout early 2026. Whether this prioritization extends to other obesity and metabolic drugs in the pipeline will be worth watching.

    How This Fits Into the GLP-1 and Obesity Treatment Landscape

    Wegovy HD does not exist in isolation. It enters a treatment landscape that has been transformed over the past five years by the GLP-1 class and continues to evolve rapidly.

    The tirzepatide comparison: Tirzepatide (Zepbound, Eli Lilly), the dual GLP-1/GIP receptor agonist approved in 2023, produces mean weight loss of approximately 20 to 22% in its pivotal SURMOUNT trials at the highest 15 mg dose, with roughly 1 in 3 participants achieving 25% or greater weight loss. The efficacy profile of Wegovy HD at 20.7% mean weight loss with similar distribution now places it in the same general range as tirzepatide, narrowing the efficacy gap that had developed after tirzepatide’s approval. No head-to-head trial comparing the two drugs has been conducted; cross-trial comparisons are unreliable and should not be used to conclude one drug is superior to the other.

    The role of step-up therapy: The availability of a higher dose within the semaglutide class provides clinicians with a titration option that did not previously exist for patients on Wegovy who needed more. Previously, the next step beyond 2.4 mg Wegovy for a patient needing greater weight reduction would have been switching to tirzepatide or considering bariatric surgery. Wegovy HD adds an intermediate option within the semaglutide class, which may be preferable for patients who are tolerating semaglutide well and want to maximize their response before considering a class switch.

    Availability: Wegovy HD became available at major retail pharmacies, telehealth partners, and through NovoCare/GoodRx channels beginning in April 2026.

    For more on how GLP-1 medications are being used beyond their original approved indications, including emerging evidence in PCOS and fertility, see our post on GLP-1 medications and PCOS: what the 2026 research actually shows.

    Who Should Consider Wegovy HD and Who Should Not

    The FDA label establishes clear parameters for appropriate use. This is not a starting-point obesity treatment, and it is not for everyone who has been on Wegovy 2.4 mg.

    May be appropriate for:

    • Adults with obesity who have been on Wegovy 2.4 mg for at least four weeks, tolerated it well, and still have clinically significant weight loss goals to meet
    • Patients with obesity-related comorbidities (cardiovascular disease, type 2 diabetes, hypertension, sleep apnea, osteoarthritis) where additional weight loss would materially change the disease course
    • Patients being evaluated for bariatric surgery who want to explore whether maximal pharmacological therapy achieves sufficient weight loss to meet their goals or reduce surgical risk

    Likely not appropriate for:

    • Treatment-naive patients (must start at lower doses and titrate per established protocol)
    • Patients who did not tolerate GI side effects at 2.4 mg
    • Patients at or near their weight management goals on the current dose
    • Patients with contraindications to semaglutide (personal or family history of MTC or MEN2, history of pancreatitis)
    • Patients who are pregnant or planning pregnancy in the near term (GLP-1 medications should be discontinued approximately two months before attempting conception)

    The cost question: Wegovy HD is a branded medication. List price for Wegovy 2.4 mg has been approximately $1,300 to $1,700 per month without insurance. Wegovy HD pricing has not been separately published as of this post. Novo Nordisk’s NovoCare savings program provides cost assistance for eligible patients. Insurance coverage for higher-dose GLP-1s for obesity (as opposed to type 2 diabetes) remains variable across payers, and prior authorization requirements are common. Patients should verify coverage before starting.

    Sources

    FDA approval and Novo Nordisk press release: Novo Nordisk A/S: Wegovy HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss. GlobeNewswire. March 19, 2026.

    Novo Nordisk US press release: FDA Approves Novo Nordisk’s New Wegovy HD Injection. PRNewswire. March 19, 2026.

    STEP UP primary publication: Wharton S, Freitas P, Hjelmesaeth J, et al; STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8

    STEP UP T2D publication: Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935-948.

    AJMC clinical coverage: Higher-Dose Semaglutide Approved Under New FDA Accelerated Review Process. AJMC. March/May 2026.

    HCPLive approval coverage: FDA Approves Higher Dose Semaglutide (Wegovy HD) Injection 7.2 mg for Obesity. HCPLive. March 2026.

    PharmExec coverage: FDA Approves Wegovy HD Injectable Under Accelerated Approval. PharmExec. March 2026.

    Wegovy 2.4 mg original FDA approval: FDA approves new drug treatment for chronic weight management in adults. FDA.gov. June 2021.

    Semaglutide mechanism reference: Semaglutide. StatPearls. NCBI.

    Weight regain after GLP-1 discontinuation: Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. PMC9183237.

    Bariatric surgery weight loss reference: Mechanick JI et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. PMC4371744.

    Tirzepatide FDA approval: FDA approves novel dual GI peptide receptor agonist for chronic weight management. FDA.gov. November 2023.

    Wegovy existing prescribing information: Wegovy prescribing information. accessdata.fda.gov.

    NovoCare patient support: novonordisk-us.com/patient-support.html

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about obesity treatment, including whether to step up to Wegovy HD, should be made in consultation with a qualified healthcare provider who can evaluate your individual health history, current medications, and weight management goals. GLP-1 medications should not be discontinued or dose-changed without clinical guidance.
  • The FDA Just Removed the Age Limit on Needle-Free Epinephrine. Here Is What Families and Caregivers Need to Know.

    The FDA Just Removed the Age Limit on Needle-Free Epinephrine. Here Is What Families and Caregivers Need to Know.

    📌 The essentials On March 27, 2026, the FDA approved a label update for neffy 1 mg (epinephrine nasal spray, ARS Pharmaceuticals) removing the minimum age requirement from the indication. Any patient weighing 33 pounds (15 kg) or more can now use neffy 1 mg for emergency treatment of Type I allergic reactions, including anaphylaxis, regardless of age. Previously, the 1 mg dose required patients to be at least 4 years old AND weigh between 33 and 66 pounds. The age floor is now gone entirely. Who this affects: approximately 25% of patients in the 33 to 66 pound weight range are under age 4, a group that was previously excluded despite meeting the weight criterion and facing real anaphylaxis risk. The label update also clarified: sniffing after administration is not required for the drug to work; the device remains usable if accidentally frozen and thawed; high-temperature exposure up to 122°F for brief periods does not compromise the product. What neffy is: a needle-free intranasal epinephrine spray that delivers epinephrine through the nasal mucosa without injection, cleared as the first non-injectable epinephrine option for anaphylaxis. Available in two doses: neffy 1 mg for patients 33 to 66 pounds (15 to 30 kg) and neffy 2 mg for patients 66 pounds or more (30 kg or more).

    Anaphylaxis is a medical emergency. It can progress from first symptoms to respiratory failure or cardiovascular collapse within minutes. The only FDA-approved first-line treatment is epinephrine, and the evidence is unambiguous: early administration saves lives. Delayed administration of epinephrine is a consistent factor in anaphylaxis fatalities.

    Yet epinephrine is frequently not given when it should be, and the reason is often not the absence of a device. It is fear of the needle.

    Multiple studies have documented that a significant proportion of caregivers, parents, and even patients delay or avoid using epinephrine autoinjectors because of needle phobia, fear of injuring the child or themselves during a high-stress emergency, or hesitation about whether the situation truly warrants injection. One survey found that fewer than half of patients at risk for anaphylaxis consistently carry their epinephrine, and non-adherence is frequently attributed to the injection format itself.

    neffy (epinephrine nasal spray) was developed specifically to address this barrier. It delivers epinephrine through the nasal mucosa without a needle. It is compact, discreet, and does not require injection technique. The March 27, 2026 label update makes it accessible to the youngest weight-eligible patients for the first time.

    What Changed and Why It Matters

    The original neffy 1 mg approval in May 2025 included a pediatric age restriction: patients using the 1 mg dose had to be at least 4 years old in addition to meeting the 33 to 66 pound weight criterion. Children under 4 who were in the eligible weight range were excluded from the labeled indication.

    The updated label removes the age floor entirely. Eligibility is now determined solely by weight: 33 pounds or more for the 1 mg dose, regardless of how old the patient is.

    This is not a small gap. Approximately 25% of patients in the 33 to 66 pound weight range are under 4 years of age. Anaphylaxis in young children is not rare. Food allergies affect approximately 8% of children, and the foods most commonly causing severe reactions in young children, including peanuts, tree nuts, milk, and egg, are foods that toddlers and preschool-aged children routinely encounter. A 3-year-old who weighs 35 pounds and has a severe peanut allergy was previously outside the labeled indication for neffy despite being in the labeled weight range. That gap is now closed.

    The Clinical Evidence Behind the Label Expansion

    The age requirement was removed based on clinical data presented to the FDA, including pharmacokinetic and pharmacodynamic evidence. Here is what the data shows.

    Pharmacokinetic equivalence to injectable epinephrine

    The original approval of neffy 1 mg was based on extensive clinical trials demonstrating that pharmacokinetic and pharmacodynamic responses in pediatric and adult subjects were consistent with those of injectable epinephrine products. This means neffy delivers comparable blood concentrations of epinephrine and produces comparable effects on blood pressure and heart rate as intramuscular autoinjector products.

    This is the pharmacological foundation of the entire neffy program: if the blood epinephrine levels achieved are equivalent, the clinical effect should be equivalent. That equivalence was established in healthy adults and pediatric subjects in the original approval.

    Real-world effectiveness data

    Since neffy’s approval, real-world prescribing data has been accumulating. Real-world data show that a single dose of neffy achieves an 89.2% symptom resolution rate in anaphylaxis, comparable to the 88.9% rate observed with intramuscular epinephrine autoinjectors. That near-identical real-world effectiveness rate across the two delivery formats is a meaningful data point for families deciding between options.

    Pediatric trial response data

    In pediatric clinical trials, 100% of patients responded to a single dose of neffy, with a median response time of 16 minutes. Adverse events in pediatric trials were generally mild and transient, consistent with the known epinephrine side effect profile (increased heart rate, pallor, tremor) rather than drug-specific adverse effects from the nasal route.

    Human factors studies

    Human factors studies demonstrated that children as young as 10 years old can use neffy effectively by following the instructions, and that untrained individuals, including babysitters, teachers, and other non-medical caregivers, can successfully administer the device in simulated emergency conditions. This real-world usability finding is as important as the pharmacokinetic data for a rescue medication whose effectiveness depends on whether it actually gets used.

    The Other Label Updates: Storage and Administration Clarifications

    The March 27 label update also includes several practical clarifications that address common questions and concerns caregivers have raised:

    What changedWhat it means in practice
    Sniffing after administration is not requiredPreviously unclear whether patients needed to sniff to pull the medication deeper into the nasal cavity. The label now clarifies that normal administration is effective regardless of whether the patient sniffs. This matters for small children who may not follow instructions during an allergic emergency.
    Accidental freezing does not render the device unusableIf neffy is accidentally frozen and thawed, it can still be used. Previously, accidental freezing was a concern that might lead caregivers to discard the device.
    High temperature excursions up to 122°F permittedBrief exposure to temperatures as high as 122°F (50°C) does not compromise product quality. This matters for devices stored in car glove compartments, diaper bags, or outdoor settings in warm climates.
    Carrying case included with each prescription cartonBeginning this summer, each carton will include a carrying case. Availability is intended to improve day-to-day portability and reduce the barrier to carrying the device consistently.

    How neffy Compares to Other Epinephrine Options

    Epinephrine remains the only FDA-approved medication for anaphylaxis. It is not optional or a second-line measure: antihistamines like diphenhydramine (Benadryl) do not treat anaphylaxis and are not substitutes. For any patient at risk for anaphylaxis, carrying epinephrine is the medical standard.

    The available options in the U.S. currently include:

    ProductFormatDoses availableWeight-based dosingAge restriction
    EpiPen / EpiPen JrIntramuscular autoinjector (spring-loaded, needle-based)0.3 mg (adult), 0.15 mg (Jr)0.15 mg for 33 to 66 lbs; 0.3 mg for 66 lbs or moreNo age floor, weight-based
    Auvi-QIntramuscular autoinjector (needle-retractable, with voice instructions)0.1 mg, 0.15 mg, 0.3 mgMultiple doses for different weight ranges including 16 to 33 lbsNo age floor, weight-based
    neffy 1 mgIntranasal spray, no needle1 mgFor patients 33 to 66 lbs (15 to 30 kg)No age floor as of March 27, 2026
    neffy 2 mgIntranasal spray, no needle2 mgFor patients 66 lbs or more (30 kg or more)No age floor

    The key practical difference is the delivery mechanism. EpiPen and Auvi-Q are effective, extensively studied intramuscular products with long track records. Auvi-Q’s voice instructions and needle-retraction design address some of the usability concerns associated with EpiPen, but both still require needle injection. neffy’s non-injectable format does not replace injection-based options but adds a choice for patients, families, and caregivers for whom needle administration is a real barrier.

    Clinically, the two approaches should be considered equivalent in terms of epinephrine delivery based on the pharmacokinetic data. The choice between them is appropriately individualized based on patient preference, caregiver confidence, and clinical judgment.

    The anaphylaxis delay problem: why needle hesitancy has clinical consequences Delayed epinephrine administration is the most common preventable factor in anaphylaxis fatalities. Studies consistently show that patients, parents, and bystanders delay using epinephrine for multiple reasons: uncertainty about whether symptoms are severe enough, concern about hurting the patient with a needle, fear of accidentally self-injecting, and lack of confidence in administering a needle device under pressure. Each minute of delay in epinephrine administration during a severe anaphylactic reaction increases the risk of cardiovascular and respiratory compromise. Antihistamines, commonly given as a first response, do not block the systemic cascade that makes anaphylaxis life-threatening. They treat urticaria (hives) and mild symptoms but cannot prevent or reverse anaphylactic shock. The clinical rationale for neffy is not that intranasal epinephrine is pharmacologically superior to injected epinephrine. The rationale is that a treatment which is equivalent in pharmacokinetics but significantly more likely to be used promptly by hesitant caregivers is clinically superior in practice, even if it is equivalent in theory.

    Dosing, Administration, and What Caregivers Need to Know

    Weight-based dosing is the rule:

    • neffy 1 mg: patients weighing 33 to 66 pounds (15 to 30 kg), any age
    • neffy 2 mg: patients weighing 66 pounds or more (30 kg or more), any age

    Administration:

    1. Remove the device from the case.
    2. Hold the device upright with your thumb on the bottom and two fingers on the nozzle.
    3. Insert the nozzle into one nostril. The patient does not need to sniff.
    4. Press firmly to release the dose.
    5. If symptoms do not improve within 5 minutes or worsen, administer a second dose in the same nostril from a second device.
    6. Call 911 or go to the nearest emergency room immediately after use, even if symptoms improve.

    Carry two devices: Current prescribing guidelines recommend carrying two epinephrine devices at all times because biphasic anaphylaxis, where symptoms return after initial improvement, can occur in approximately 1 in 5 anaphylaxis events.

    Storage guidance: neffy can be stored at room temperature. Brief exposure up to 122°F is permitted. If accidentally frozen, it can be thawed and used. Keep the cap on between uses. The shelf life is 24 months at room temperature.

    When to call 911: Always. Even after epinephrine administration and apparent symptom improvement, anaphylaxis requires emergency medical evaluation because of biphasic reaction risk.

    What This Means for Schools, Daycares, and Emergency Preparedness

    The removal of the age restriction has implications beyond individual families. Schools and daycare facilities with anaphylaxis emergency plans now have an additional option to consider for their youngest students who meet weight criteria. Many early childhood programs struggle with the needle administration training requirements that injectable epinephrine demands of staff, and untrained-user data showing effective neffy administration by non-medical personnel is directly relevant in these settings.

    FARE (Food Allergy Research and Education) maintains resources for schools navigating food allergy emergency planning. ACAAI (American College of Allergy, Asthma and Immunology) provides clinical guidance on anaphylaxis preparedness. Both organizations’ resources may be updated to reflect the age restriction removal.

    Sources

    ARS Pharmaceuticals press release (March 27, 2026): ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label. GlobeNewswire.

    ARS Pharmaceuticals IR page: ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement. ir.ars-pharma.com.

    Original neffy 1 mg approval (May 2025): ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg. ir.ars-pharma.com.

    FDA drug approval page: FDA approves epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. FDA.gov.

    Pharmacy Times coverage: FDA Removes Age Restriction for neffy 1 mg, Expanding Access to Needle-Free Epinephrine. pharmacytimes.com. March 2026.

    Contemporary Pediatrics coverage (with 89.2% real-world data): FDA removes age restriction for epinephrine nasal spray. contemporarypediatrics.com. March 2026.

    Epinephrine delay and anaphylaxis fatalities: Epinephrine Use and Barriers to Carrying. PMC6290645.

    Anaphylaxis overview: AAAAI Anaphylaxis.

    Food allergy statistics: Facts and Statistics. FARE.

    Patient and caregiver resources: FARE: Food Allergy Research and Education | ACAAI Anaphylaxis | AAAAI Anaphylaxis | neffy prescribing information

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Patients with known or suspected anaphylaxis risk should work with a board-certified allergist or immunologist to establish an individualized emergency action plan. Always call 911 after epinephrine administration, even if symptoms appear to resolve.
  • Once-Weekly Navepegritide Is Now FDA-Approved for Children With Achondroplasia. Here Is What the APPROACH Trial Data Actually Shows.

    Once-Weekly Navepegritide Is Now FDA-Approved for Children With Achondroplasia. Here Is What the APPROACH Trial Data Actually Shows.

    📌 The essentials On February 27, 2026, the FDA approved YUVIWEL (navepegritide, Ascendis Pharma) under the Accelerated Approval Program for increasing linear growth in children aged 2 years and older with achondroplasia with open epiphyses. This is the first and only once-weekly treatment for achondroplasia and the only approved therapy that provides continuous systemic CNP exposure over the weekly dosing interval. The clinical basis: The Phase 2b APPROACH randomized controlled trial (NCT05598320) published in JAMA Pediatrics (November 2025) showed annualized growth velocity (AGV) of 5.84 cm/year with navepegritide versus 3.88 cm/year with placebo (p less than 0.0001), a difference of nearly 2 cm/year additional growth. Accelerated approval context: continued approval may be contingent on confirmatory trials verifying long-term clinical benefit. AGV is the accepted surrogate endpoint; long-term height and functional outcomes are the subject of ongoing follow-up. How it compares: the only other approved therapy for achondroplasia is vosoritide (Voxzogo, BioMarin), approved in 2021, which requires daily injection. YUVIWEL is weekly. Neither has been compared head-to-head in a clinical trial. Rare Pediatric Disease Priority Review Voucher granted alongside this approval. Commercial availability: expected early Q2 2026.

    Achondroplasia is the most common form of skeletal dysplasia, affecting approximately 1 in 15,000 to 40,000 live births worldwide. It is caused by a gain-of-function mutation in the FGFR3 gene that overactivates a signaling pathway limiting endochondral bone growth. For decades, treatment was supportive, focused on managing the complications of the condition rather than addressing its underlying biology. That began to change in 2021, when the FDA approved the first drug targeting the root cause of achondroplasia. On February 27, 2026, a second drug entered clinical use offering the same mechanistic approach with a meaningful practical difference: once-weekly dosing instead of once-daily.

    YUVIWEL (navepegritide) was developed by Ascendis Pharma using their TransCon technology. Its FDA approval under the Accelerated Approval Program makes it the first and only once-weekly treatment for achondroplasia, supported by robust Phase 2b trial data published in JAMA Pediatrics and presented at major pediatric endocrinology meetings.

    What Achondroplasia Is and Why It Extends Beyond Height

    To understand what navepegritide does, it helps to understand what achondroplasia actually is, because the condition is more than a difference in stature.

    Achondroplasia causes characteristic skeletal features including short stature with rhizomelic (proximal limb) shortening, enlarged head circumference with midface hypoplasia, exaggerated lumbar lordosis, and bowed legs. The average adult height in achondroplasia is approximately 4 feet 1 inch (125 cm) in women and 4 feet 4 inches (131 cm) in men. But height is one dimension of the condition’s impact.

    Achondroplasia is a multisystem condition. Many affected individuals face:

    • Spinal cord compression at the foramen magnum, which can cause central apnea and is the leading cause of sudden death in infancy in achondroplasia
    • Spinal stenosis in adulthood, causing pain, weakness, and neurological symptoms
    • Obstructive sleep apnea, occurring in a majority of affected children
    • Recurrent otitis media and associated hearing loss due to midface hypoplasia
    • Varus deformity (bowing) of the lower extremities affecting mobility and joint health

    This multisystem burden is why the pediatric orthopedic and skeletal dysplasia research community frames achondroplasia pharmacotherapy in terms of improving overall skeletal development, not simply maximizing height. The APPROACH trial endpoints reflect this: in addition to AGV, the trial measured tibial-femoral angle, mechanical axis deviation, fibula-to-tibia length ratio, and the Achondroplasia Child Experience Measure for physical functioning.

    The Mechanism: CNP and the FGFR3 Pathway

    The biology behind navepegritide requires understanding what the FGFR3 mutation actually does and how CNP counteracts it.

    In normal bone growth, endochondral ossification converts cartilage to bone at growth plates. This process depends on chondrocyte (cartilage cell) proliferation and differentiation being maintained at the appropriate rate. FGFR3 (fibroblast growth factor receptor 3) normally acts as a brake on this process. In achondroplasia, the gain-of-function FGFR3 mutation overactivates this brake through the MAPK signaling pathway, suppressing chondrocyte proliferation and slowing bone elongation.

    C-type natriuretic peptide (CNP) is a naturally occurring peptide that counteracts FGFR3-MAPK signaling. By activating its receptor (NPR-B) in chondrocytes, CNP inhibits the overactivated MAPK pathway, supporting more normal chondrocyte proliferation and therefore more normal bone growth. The therapeutic logic is to restore CNP-mediated inhibition of the overactive FGFR3 pathway.

    Navepegritide is a CNP analog prodrug. “Prodrug” means it is administered in an inactive or slowly releasing form that is converted to active CNP in the body over time. Ascendis Pharma’s TransCon technology uses a hydrolytically cleavable linker to attach CNP to an inert carrier. After subcutaneous injection, the linker degrades slowly, releasing active CNP at a controlled, continuous rate over approximately seven days, matching the weekly dosing interval. This sustained release is the key pharmacological advance over vosoritide, which has a short half-life requiring daily injection to maintain therapeutic CNP exposure.

    The APPROACH Trial: What the Evidence Shows

    Trial design

    The APPROACH trial (NCT05598320) was a Phase 2b, randomized, double-blind, placebo-controlled study enrolling 84 children aged 2 to 11 years with achondroplasia across seven countries. Participants were randomized 2:1 to receive navepegritide 100 μg/kg subcutaneously once weekly or placebo for 52 weeks, followed by a single-arm open-label extension (OLE) in which placebo-treated children crossed over to navepegritide.

    The primary endpoint was annualized growth velocity (AGV) at week 52. Secondary endpoints included changes in skeletal proportionality measures (tibial-femoral angle, mechanical axis deviation, fibula-to-tibia length ratio) and the Achondroplasia Child Experience Measure for physical functioning.

    52-week results

    EndpointNavepegritidePlaceboSignificance
    Annualized growth velocity (AGV)5.84 cm/year3.88 cm/yearp less than 0.0001
    Difference in AGV (LS mean)+1.96 cm/yearReferenceStatistically significant
    Tibial-femoral angleImprovedNo improvementSignificant
    Mechanical axis deviationImprovedNo improvementSignificant
    Fibula-to-tibia length ratioImprovedNo improvementSignificant
    Physical functioning (ACH-CPM)ImprovedNo improvementSignificant
    Safety: grade 3 or higher AEs related to drugNone reported—Favorable

    Source: Savarirayan R et al. JAMA Pediatrics. 2025;180(1):18-25. doi:10.1001/jamapediatrics.2025.4771. PMC12624480.

    The nearly 2 cm/year additional AGV over placebo is the headline number. To contextualize it: untreated children with achondroplasia typically grow at rates substantially below age-matched peers without the condition. Adding nearly 2 cm/year of growth velocity, across years of treatment, could translate to several centimeters of additional stature by the end of linear growth, though height is a secondary consideration given the bone proportionality and functional improvements also observed.

    The improvements in tibial-femoral angle and mechanical axis deviation are clinically significant beyond their contribution to height. These measurements reflect the degree of lower limb bowing that is common in achondroplasia and contributes to gait abnormalities, knee pain, and long-term joint health. Improving these parameters addresses functional and structural aspects of the condition, not just growth velocity.

    The Achondroplasia Child Experience Measure for physical functioning is a validated patient-reported outcome instrument assessing how children experience the physical limitations of achondroplasia in daily activities. Its improvement alongside the growth and skeletal endpoints indicates that the trial captured changes meaningful to the children themselves, not only measurements observable on radiographs.

    Two-year data (May 2026 update)

    In May 2026, Ascendis presented two-year APPROACH trial data showing pronounced gains specifically in children aged 5 years and older. In this subgroup, navepegritide produced AGV of 5.84 cm/year (observed mean) versus 3.88 cm/year on placebo over the initial 52 weeks, with durable benefit sustained through the open-label extension. The company also presented data from the combination navepegritide plus lonapegsomatropin (once-weekly growth hormone) program, which showed mean AGV of 8.80 cm/year in treatment-naive children and exceeded the 97th-percentile AGV of average-stature children after 52 weeks, though this combination is investigational and not yet approved.

    Accelerated Approval: What It Means Here

    The FDA granted YUVIWEL approval under the Accelerated Approval Program, which allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit. The surrogate endpoint for YUVIWEL is annualized growth velocity.

    Continued approval is contingent on verification of clinical benefit in confirmatory trials. Ascendis is conducting confirmatory long-term studies evaluating final adult height and clinical functional outcomes. This is standard practice for accelerated approvals in rare pediatric diseases and does not mean the drug’s efficacy is uncertain; it means that the FDA has determined the available evidence is sufficient for approval now while longer-term confirmatory data is generated.

    YUVIWEL vs. vosoritide (Voxzogo): how they compare Vosoritide (Voxzogo, BioMarin) was the first disease-targeting drug approved for achondroplasia, in August 2021. It is a CNP analog but not a prodrug: it requires daily subcutaneous injection because its active form degrades quickly in the body. Navepegritide is a prodrug using TransCon technology to achieve weekly dosing through sustained release, providing continuous CNP exposure over the dosing interval rather than daily peaks and troughs. Both target the same CNP-FGFR3 pathway. Neither has been directly compared in a head-to-head randomized trial. The evidence for vosoritide’s efficacy comes from the pivotal ACH-003 trial, which showed a difference of 1.57 cm/year in AGV versus placebo. The APPROACH trial showed a 1.96 cm/year difference for navepegritide versus placebo. Cross-trial comparisons are unreliable and should not be used to conclude one drug is superior. The clinically relevant difference for families is dosing schedule: once-weekly versus once-daily injection. For young children, the reduction in injection frequency is a meaningful quality-of-life consideration.

    Safety Profile

    The safety profile of navepegritide in the APPROACH trial was favorable, with no grade 3 or higher adverse events attributed to the drug. The most common adverse events were consistent with the expected profile of a subcutaneous injection therapy in children:

    • Injection site reactions (most common, typically mild and transient)
    • Headache
    • Fever
    • Vomiting
    • Upper respiratory symptoms

    No new safety signals were identified in the extended follow-up period. The full prescribing information includes complete safety data and monitoring recommendations.

    Regulatory Designations

    YUVIWEL received multiple FDA designations supporting its development:

    As discussed in our post on the first gene therapy for genetic deafness, the Rare Pediatric Disease Priority Review Voucher is a transferable incentive granted upon approval of therapies for rare pediatric conditions. It can be used by Ascendis or sold to another pharmaceutical company to accelerate a different drug’s FDA review, and has market value in the hundreds of millions of dollars. The voucher program exists specifically to incentivize development of treatments for conditions affecting small pediatric populations where commercial markets alone would not support development costs.

    What This Approval Means for Families

    For a child aged 2 to 11 years with achondroplasia and open growth plates, YUVIWEL is now an FDA-approved treatment option. The practical question for most families will be a conversation with a pediatric endocrinologist or geneticist at a center specializing in skeletal dysplasia about whether navepegritide or vosoritide is the right choice for their child’s specific situation.

    Key considerations include the child’s current growth trajectory, whether they are already on vosoritide, family preference for injection frequency, and access and insurance coverage. YUVIWEL is expected to be available through commercial channels beginning early Q2 2026.

    For families with children being managed at a skeletal dysplasia center, this conversation should be initiated with the treating team. For families who do not have access to specialized skeletal dysplasia care, the Achondroplasia & Hypochondroplasia Alliance, Little People of America, and the National Organization for Rare Disorders (NORD) maintain physician referral resources, patient community networks, and current information on treatment options.

    ClinicalTrials.gov lists ongoing navepegritide trials including the adolescent trial (NCT06732895) for ages 12 to 18 and the combination lonapegsomatropin trial, for families interested in investigational options beyond the current approval.

    For related coverage of rare pediatric disease FDA approvals, see our posts on the first gene therapy for genetic deafness approved under the Rare Pediatric Disease PRV program and the UX111 gene therapy for Sanfilippo syndrome now under FDA review.

    Sources

    Ascendis Pharma FDA approval press release: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older. GlobeNewswire. February 27, 2026.

    APPROACH trial primary publication: Savarirayan R, McDonnell C, Bacino CA, et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. JAMA Pediatrics. 2025;180(1):18-25. doi:10.1001/jamapediatrics.2025.4771. PMC12624480.

    APPROACH trial registration (Phase 2b): NCT05598320. ClinicalTrials.gov.

    Two-year APPROACH data (May 2026): New 2-Year Data from Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged 5 Years. GlobeNewswire. May 6, 2026.

    Pediatric Endocrine Society clinical review: Navepegritide (Yuviwel) for Children with Achondroplasia: New Drugs and Therapeutics. pedsendo.org. March 2026.

    Contemporary Pediatrics approval coverage: FDA Issues Historic Approval for Navepegritide in Achondroplasia. contemporarypediatrics.com. 2026.

    Combination therapy data (HCPLive): Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial. hcplive.com. February 2026.

    Adolescent trial registration: NCT06732895. ClinicalTrials.gov.

    Vosoritide FDA approval: FDA approves vosoritide for achondroplasia. FDA.gov. August 2021.

    YUVIWEL prescribing information: YUVIWEL (navepegritide) full prescribing information. accessdata.fda.gov.

    Achondroplasia NORD overview: Achondroplasia. NORD.

    NIH GARD achondroplasia: Achondroplasia. rarediseases.info.nih.gov.

    CNP biology reference: C-type natriuretic peptide and bone growth. PMC3482906.

    Endochondral ossification reference: Endochondral Ossification. StatPearls. NCBI.

    Accelerated Approval pathway: Accelerated Approval Program. FDA.gov.

    Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

    Patient resources: Achondroplasia & Hypochondroplasia Alliance | Little People of America | NORD: Achondroplasia | ClinicalTrials.gov: navepegritide

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about treatment for children with achondroplasia should be made in close consultation with a pediatric endocrinologist, geneticist, or specialist in skeletal dysplasia familiar with the child’s individual growth history and clinical circumstances.

  • Ovarian Cancer Has Resisted Almost Every Drug Thrown at It in the Platinum-Resistant Setting. Lifyorli™ Just Changed That by Targeting Cortisol.

    Ovarian Cancer Has Resisted Almost Every Drug Thrown at It in the Platinum-Resistant Setting. Lifyorli™ Just Changed That by Targeting Cortisol.

    📌 The essentials On March 25, 2026, the FDA approved Lifyorli (relacorilant, Corcept Therapeutics) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. This is a full approval based on overall survival data, not accelerated approval. The mechanism: relacorilant is an oral, selective glucocorticoid receptor (GR) antagonist. It blocks cortisol’s tumor-protective action that suppresses apoptosis in cancer cells, sensitizing them to nab-paclitaxel’s cytotoxic effect. Dosing: relacorilant 150 mg orally on the day before, day of, and day after each nab-paclitaxel infusion, given in 28-day cycles. The clinical basis: Phase 3 ROSELLA trial (NCT05257408), published in The Lancet, showing median overall survival of 16.0 versus 11.9 months (HR 0.65; p=0.0004), a 35% reduction in risk of death. The 18-month OS rate was 46% versus 27%. NCCN has designated relacorilant plus nab-paclitaxel as a preferred regimen for platinum-resistant ovarian cancer.

    For roughly thirty years, the story of platinum-resistant ovarian cancer has been one of persistent failure. Trial after trial. Checkpoint inhibitor after checkpoint inhibitor. PARP inhibitor combinations. Antibody-drug conjugates. Antiangiogenics beyond bevacizumab. The disease has resisted almost everything, and the graveyard of Phase 3 trials that failed in this setting is long and dispiriting.

    Platinum-resistant ovarian cancer is defined by a clinical reality: the cancer progresses within six months of completing platinum-based chemotherapy. At that point, the treatment options narrow sharply. Single-agent non-platinum chemotherapy, including pegylated liposomal doxorubicin, paclitaxel, gemcitabine, and topotecan, with or without bevacizumab, has been the mainstay. Response rates are modest. Survival is poor.

    On March 25, 2026, the FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is the first FDA-approved selective glucocorticoid receptor antagonist, a category of drug that does not target the tumor directly, but instead targets the role cortisol plays in helping tumors resist the chemotherapy meant to kill them. The pivotal ROSELLA trial, published simultaneously in The Lancet, delivered something this disease has not seen in a long time: a statistically robust overall survival improvement.

    The Disease: Why Platinum-Resistant Ovarian Cancer Is So Hard to Treat

    Ovarian cancer is the most lethal gynecologic malignancy. In 2024, an estimated 320,000 new cases were diagnosed globally and approximately 210,000 women died from the disease, accounting for about 4.8% of all cancer-related mortality. In the United States, ovarian cancer kills approximately 12,800 women annually. The high mortality relative to incidence reflects a disease that is typically diagnosed at advanced stage (III or IV), when cure is unlikely.

    Platinum-based chemotherapy, carboplatin and cisplatin, has been the backbone of ovarian cancer treatment for three decades. Most patients initially respond well. The problem is recurrence: approximately 70% of patients with advanced ovarian cancer will relapse, and through successive platinum cycles, resistance becomes inevitable. Once a patient’s cancer progresses within six months of the last platinum regimen, they are classified as platinum-resistant, and the therapeutic landscape changes dramatically for the worse.

    Why this setting has been so difficult: the failed trials The list of Phase 3 trials that failed to improve overall survival in platinum-resistant ovarian cancer is extensive. Checkpoint inhibitors have largely disappointed in ovarian cancer despite transforming outcomes in melanoma, lung cancer, and other solid tumors. The ARTISTRY-7 trial, evaluating nemvaleukin plus pembrolizumab versus chemotherapy, was negative. The underlying biology is partially explanatory: ovarian tumors often have immunosuppressive microenvironments with low T-cell infiltration, limited PD-L1 expression, and mechanisms that actively exclude immune cells. Notably, the ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab plus paclitaxel plus or minus bevacizumab in platinum-resistant ovarian cancer did ultimately produce the first significant PFS and OS benefit with immunotherapy in this setting. That approval, covered here on Health Evidence Digest, required PD-L1 CPS of 1 or higher for the indicated population. For patients who do not meet that biomarker threshold or who have progressed after immunotherapy, the unmet need remained enormous. What was needed for that broader population was a different angle of attack entirely.

    The Mechanism: Cortisol as a Shield for Tumor Cells

    The biological rationale for relacorilant starts with a question that oncologists have long observed but had limited tools to address: why does chemotherapy work initially in ovarian cancer, then stop working? Part of the answer involves the tumor microenvironment, and specifically the role cortisol plays within it.

    Cortisol is a glucocorticoid hormone produced by the adrenal glands that regulates stress responses, inflammation, and immune function. In normal physiology, cortisol plays many important and beneficial roles. In tumor biology, however, cortisol, acting through the glucocorticoid receptor (GR) expressed in many cancer cell types, contributes to chemotherapy resistance through a specific and well-characterized mechanism: it inhibits apoptosis.

    Apoptosis is programmed cell death, the cellular self-destruct mechanism that chemotherapy is specifically designed to trigger. Taxane chemotherapies like nab-paclitaxel work by disrupting microtubule function during cell division, causing mitotic arrest and ultimately apoptotic cell death. When cortisol activates GR signaling in tumor cells, it suppresses the apoptotic machinery, effectively giving those cells a cortisol-mediated shield against the chemotherapy that should be killing them.

    Relacorilant is an oral, selective glucocorticoid receptor antagonist. It competes with cortisol at the GR binding site, blocking the receptor without activating it. With GR signaling suppressed, cortisol’s protection of tumor cells from apoptosis is reduced, and the tumor cells become more sensitive to nab-paclitaxel’s intended mechanism. Relacorilant is selective: it binds only to the glucocorticoid receptor, not to the progesterone, androgen, mineralocorticoid, or estrogen receptors. This selectivity is what distinguishes it from older, non-selective glucocorticoid antagonists like mifepristone.

    The dosing schedule and why it matters for tolerability Relacorilant is taken orally at 150 mg on three specific days per 28-day cycle: the day before each nab-paclitaxel infusion, the day of the infusion, and the day after. Nab-paclitaxel is administered intravenously on days 1, 8, and 15 of each cycle. This intermittent dosing design is intentional. Continuous glucocorticoid receptor blockade would interfere with the body’s normal cortisol-dependent functions, including immune regulation, glucose metabolism, and stress response. By limiting GR blockade to the three days surrounding each chemotherapy infusion, the regimen specifically targets the period when cortisol’s tumor-protective effects are most relevant, while minimizing disruption to normal physiology. This design choice is supported by the trial’s safety data: no cases of adrenal insufficiency were reported in the ROSELLA trial.

    The ROSELLA Trial: Design and Full Results

    The Phase 3 ROSELLA trial (NCT05257408) was an international, randomized, controlled, open-label study conducted across 117 sites in 14 countries, including the United States, multiple European nations, South Korea, Brazil, Argentina, Canada, and Australia, in collaboration with the GOG Foundation, ENGOT, APGOT, LACOG, and ANZGOG. Enrollment ran from January 2023 to April 2024.

    Patient population

    Eligible patients were adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, defined as disease progression within six months of the last platinum-based therapy. All had received one to three prior systemic therapy regimens, and all had prior bevacizumab exposure. Patients requiring chronic corticosteroids were excluded. The median patient age was 61 to 62 years.

    Randomization and treatment

    381 patients were randomized 1:1 to relacorilant 150 mg plus nab-paclitaxel 80 mg/m² (n=188), or nab-paclitaxel alone at 100 mg/m² (n=193). The monotherapy arm received a higher dose of nab-paclitaxel to reflect the absence of a chemo-sensitizing partner. The dual primary endpoints were progression-free survival (PFS) by RECIST 1.1 and blinded independent central review, and overall survival.

    Results

    EndpointRelacorilant plus nab-paclitaxelNab-paclitaxel alone
    Median overall survival16.0 months (95% CI 13.0 to 18.3)11.9 months (95% CI 10.0 to 13.8)
    OS hazard ratio0.65 (95% CI 0.51 to 0.83)Reference
    OS p-value0.0004—
    Reduction in risk of death35%—
    12-month OS rate60%50%
    18-month OS rate46%27%
    Median PFS (BICR)6.5 months (95% CI 5.6 to 7.4)5.5 months (95% CI 3.9 to 5.9)
    PFS hazard ratio0.70 (95% CI 0.54 to 0.91)Reference
    PFS p-value0.0076—
    Reduction in risk of progression30%—
    12-month PFS rate25%13%
    Second PFS (PFS2) hazard ratio0.73 (p=0.0037)Reference

    Source: Olawaiye AB et al. The Lancet. 2026. doi:10.1016/S0140-6736(26)00462-9. ROSELLA trial (NCT05257408).

    The OS data maturity at the final analysis was 76%, meaning three-quarters of patients had experienced the endpoint, making this a robust and interpretable dataset. The Lancet publication notes that the Kaplan-Meier survival curves show progressively widening separation over time, suggesting durable benefit rather than early separation that converges. The 18-month OS rate difference — 46% versus 27% — is particularly striking: at 18 months, nearly half of patients on the combination were still alive, compared with just over one-quarter on chemotherapy alone.

    The benefit was consistent across all prespecified subgroups, including patients who had received two versus three prior lines of therapy, those with prior PARP inhibitor exposure, and across geographic regions. No biomarker selection was required for eligibility or benefit, which means the improvement applies to the broad platinum-resistant ovarian cancer population, not a molecularly defined subset.

    The principal investigator of the ROSELLA trial, Dr. Alexander B. Olawaiye, MD, Director of Gynecologic Cancer Research at Magee-Womens Hospital of UPMC, characterized the finding at the SGO Late-Breaker presentation as the first demonstration that modulating the steroid receptor pathway, specifically the glucocorticoid receptor, can produce benefit in the treatment of platinum-resistant ovarian cancer, noting that the uniqueness of the pathway makes this new in every way.

    Safety: What the Data Shows

    The combination arm had a higher rate of grade 3 or higher treatment-emergent adverse events than the monotherapy arm: 74.5% versus 59.5%. The primary driver was hematologic toxicity, particularly neutropenia (44% versus 25% in the combination arm) and anemia (18% versus 9%). These findings reflect the addition of any chemotherapy-sensitizing agent and are consistent with what clinicians encounter in other combination regimens.

    Adverse event (20% or higher incidence)Combination armMonotherapy arm
    Decreased hemoglobinMost common, all gradesLower rate
    Neutropenia (grade 3 or higher)44%25%
    Fatigue20% or higherPresent
    Nausea20% or higherPresent
    Diarrhea20% or higherPresent
    Decreased platelets20% or higherPresent
    Rash20% or higherPresent
    Decreased appetite20% or higherPresent
    Anemia (grade 3 or higher)18%9%
    Adrenal insufficiency0 cases0 cases
    Deaths attributed to relacorilant00

    Two specific safety findings deserve emphasis. First, no cases of adrenal insufficiency were observed, validating the intermittent dosing design. Second, peripheral neuropathy, a known concern with taxane chemotherapy, occurred at similar rates in both arms, suggesting relacorilant did not worsen this chemotherapy-related toxicity.

    The prescribing label carries a contraindication for patients who require corticosteroids for a life-saving indication, because GR blockade would impair their effectiveness. Patients on systemic corticosteroids for severe asthma, inflammatory bowel disease, or immunosuppression following transplant require careful evaluation before initiating Lifyorli. Prescribing information warnings include neutropenia and severe infection risk, adrenal insufficiency monitoring, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.

    What This Approval Represents

    The NCCN Clinical Practice Guidelines in Oncology added Lifyorli plus nab-paclitaxel as a preferred regimen for platinum-resistant ovarian cancer following the approval. That designation reflects the committee’s assessment that the overall survival data from ROSELLA represents a meaningful advance for a patient population with very limited meaningful advances over the past decade.

    Three aspects of the ROSELLA data deserve specific emphasis as markers of robustness. The OS analysis is mature: 76% data maturity is high for an ongoing survival analysis and ensures the hazard ratio estimate is reliable. Subsequent therapies were balanced between the two arms, ruling out the possibility that post-progression treatment differences explain the survival benefit. And the benefit was consistent across all predefined subgroups, including those heavily pretreated and those with prior PARP inhibitor exposure.

    What we do not yet know: open questions for clinical practice No biomarker predicted response. ROSELLA enrolled without biomarker selection and found benefit across all subgroups. That is good news for broad access, but it means there is not yet a way to identify which patients are most likely to respond, or whether some patients have particularly high GR expression that drives greater benefit. Corcept and academic collaborators are likely studying this as a post-approval research question. Patient-reported quality of life. The ROSELLA trial included EORTC quality-of-life measures as secondary endpoints. Full patient-reported outcome analysis had not been comprehensively presented at time of writing. For patients in this setting, tolerability and quality of remaining life matter alongside survival data. Relacorilant in other tumor types. Corcept has active or planned trials of relacorilant in platinum-sensitive ovarian cancer, endometrial cancer, cervical cancer, pancreatic cancer, and prostate cancer. The proof-of-concept from ROSELLA that GR antagonism can sensitize tumors to chemotherapy may accelerate these programs.

    Regulatory Status and Access

    FDA approval

    Approved March 25, 2026, for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. This is a full approval, based on overall survival data from ROSELLA meeting both co-primary endpoints.

    European Medicines Agency

    Corcept has submitted a Marketing Authorisation Application (MAA) to the EMA for relacorilant in platinum-resistant ovarian cancer. Relacorilant has received orphan drug designation from the European Commission for ovarian cancer treatment. The EMA review is ongoing.

    Patient support

    Corcept has established Lifyorli Support for patients and healthcare providers at 1-855-439-6754 (1-85-LIFYORLI). For questions about eligibility, prior authorization support, or financial assistance programs, this is the recommended first contact.

    For patients and families navigating platinum-resistant ovarian cancer, the Ovarian Cancer Research Alliance and the Foundation for Women’s Cancer both maintain updated treatment information, clinical trial directories, and peer support resources. For related HED coverage of ovarian cancer treatment advances in 2026, see our post on pembrolizumab becoming the first approved immunotherapy for platinum-resistant ovarian cancer and our analysis of vepdegestrant and the PROTAC mechanism in breast cancer as examples of how novel mechanisms of action are reshaping gynecologic and breast oncology in the same period.

    Sources

    FDA approval: FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA.gov. March 25, 2026.

    Corcept press release (approval): FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist. ir.corcept.com. March 25, 2026.

    Corcept press release (SGO/OS data): Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet. ir.corcept.com. April 10, 2026.

    Primary OS publication: Olawaiye AB et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. The Lancet. 2026. doi:10.1016/S0140-6736(26)00462-9

    PFS publication: Lorusso D et al. ROSELLA: a phase 3 study of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. The Lancet. 2025;405:2205-2216.

    ROSELLA trial registration: NCT05257408. ClinicalTrials.gov.

    CancerNetwork OS coverage: Relacorilant/Nab-Paclitaxel Reduces Risk of Death by 35% in Platinum-Resistant Ovarian Cancer. cancernetwork.com. April 2026.

    CURE coverage: Lifyorli Combo Approved in Platinum-Resistant Ovarian Cancer. curetoday.com. March 2026.

    Targeted Oncology: Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer. targetedonc.com. April 2026.

    PROC treatment landscape: Current Treatments, Future Strategies for Platinum-Resistant Ovarian Cancer. AJMC. March 2026.

    PROC unmet need review: Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance. PubMed. 2023. PMID:37079311.

    NCCN guidelines: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. NCCN.

    Glucocorticoid receptor biology: Glucocorticoid Receptor Signaling in Cancer. PMC7694440.

    Apoptosis reference: Apoptosis. StatPearls. NCBI.

    Cortisol overview: Cortisol. StatPearls. NCBI.

    RECIST/PFS methodology: New Response Evaluation Criteria in Solid Tumours. PMC3107543.

    Checkpoint inhibitors in ovarian cancer: Immune Checkpoint Inhibitors in Ovarian Cancer. PMC7174922.

    PARP inhibitors: PARP Inhibitors. cancer.gov.

    Neutropenia: Neutropenia. StatPearls. NCBI.

    Patient resources: Ovarian Cancer Research Alliance | Foundation for Women’s Cancer | NCCN Ovarian Cancer Guidelines | Lifyorli Support: 1-855-439-6754

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for platinum-resistant ovarian cancer should be made in consultation with a qualified gynecologic oncologist.

  • The KRESLADI Trial Data That Just Earned the First Gene Therapy Approval for LAD-I

    The KRESLADI Trial Data That Just Earned the First Gene Therapy Approval for LAD-I

    📌 The essentials On March 26, 2026, the FDA approved KRESLADI (marnetegragene autotemcel, Rocket Pharmaceuticals), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I), indicated specifically for pediatric patients who lack an available HLA-matched sibling donor. The clinical basis: a Phase 1/2 trial (NCT03812263) enrolling 9 children with molecularly confirmed severe LAD-I, showing 100% HSCT-free survival at one year (95% CI 66 to 100; p less than 0.001), 0 graft failures, and sustained neutrophil CD18 expression through median 4.2-year follow-up. Results published in the New England Journal of Medicine. This is an accelerated approval based on biomarker surrogates (CD18 and CD11a expression). Confirmatory post-marketing studies are required. Rare Pediatric Disease Priority Review Voucher granted alongside approval. The boxed warning: lentiviral vector-mediated insertional oncogenesis, requiring long-term post-treatment monitoring.

    Most children born with severe Leukocyte Adhesion Deficiency Type I do not survive to their second birthday without treatment. Their white blood cells, the immune system’s first responders, lack a critical surface protein called CD18 that allows them to exit the bloodstream and reach the site of infection. Without it, bacteria and fungi go virtually unchallenged. The infections are relentless, poorly responsive to antibiotics, and frequently fatal. Omphalitis, infection of the umbilical stump, is sometimes the first sign, in a newborn just days old.

    The only curative option before March 2026 was an allogeneic hematopoietic stem cell transplant from an HLA-matched sibling donor. Most children do not have one. Transplants from mismatched donors carry substantial risks: graft failure, graft-versus-host disease, and transplant-related mortality. Some families faced a situation with no good path forward.

    On March 26, 2026, the FDA approved KRESLADI (marnetegragene autotemcel), the first gene therapy for severe LAD-I, indicated specifically for pediatric patients without an available matched sibling donor. The clinical trial behind it enrolled nine children. None had graft failure. All survived. The youngest were infants; all who were enrolled under age one were alive beyond age two. The data was published in the New England Journal of Medicine.

    Leukocyte Adhesion Deficiency Type I: What It Is and Why It Kills

    LAD-I is caused by biallelic (two-copy) loss-of-function mutations in the ITGB2 gene, which encodes CD18, the beta-2 integrin subunit that pairs with CD11 proteins to form integrin complexes on the surface of leukocytes. These CD11/CD18 complexes, particularly LFA-1, composed of CD11a and CD18, are what allow white blood cells to adhere to the inner walls of blood vessels and migrate through them into infected tissues. Without functional CD18, neutrophils and other leukocytes stay in circulation. They cannot reach wounds. They cannot engulf bacteria at infection sites. Infections that a healthy immune system would clear in days become life-threatening emergencies.

    Severe LAD-I is defined by CD18 surface expression below 2% of normal. At this level, even minor infections, a skin abrasion, a gum infection, the umbilical cord stump, can become life-threatening. The infection burden is compounded by delayed wound healing: without leukocyte migration, the inflammatory cascade needed for tissue repair does not function properly.

    How rare is LAD-I? The incidence of LAD-I in the U.S. is estimated at approximately 1 in 100,000 to 1 in 200,000 live births. Roughly two-thirds of affected patients have the severe form. Based on approximately 3.6 million U.S. births per year, that translates to roughly 12 to 24 new cases of severe LAD-I annually in the United States. Global prevalence is higher in regions where consanguineous marriage is more common, as LAD-I is autosomal recessive, meaning a child must inherit one mutated ITGB2 copy from each parent. In some Middle Eastern and South Asian populations, the disease burden is proportionally higher. The ultra-rarity of the disease is part of why gene therapy development has been slow: a clinical trial enrolling 9 patients represents a meaningful fraction of the total global patient population who meet enrollment criteria at any given time.

    How KRESLADI Works: Lentiviral Gene Correction of the Patient’s Own Stem Cells

    KRESLADI is an autologous gene therapy, meaning it is manufactured from the patient’s own cells, corrected in the laboratory, and returned to the same patient. This eliminates the core risk of donor-based transplantation: immune mismatch. There is no foreign tissue to reject, and no graft to mount an attack against the host.

    The manufacturing process follows a sequence of steps before the patient receives a single intravenous infusion:

    Mobilization and apheresis: The patient receives drugs (G-CSF and/or plerixafor) to mobilize hematopoietic stem cells (HSCs) from the bone marrow into the bloodstream. These CD34+ progenitor cells are then collected by apheresis, a process that filters blood through a machine and harvests stem cells.

    Ex vivo gene correction: The harvested CD34+ cells are taken to a manufacturing facility and transduced with a lentiviral vector carrying a functional copy of the ITGB2 gene. The lentiviral vector integrates into the cell genome, providing a permanent genetic correction. A back-up collection of unmodified CD34+ cells is preserved in case engraftment fails.

    Myeloablative conditioning: Before infusion, the patient undergoes full myeloablative conditioning, high-dose chemotherapy designed to eliminate the existing defective bone marrow and create space for the corrected cells to engraft. This is a significant clinical intervention and the primary source of short-term treatment-related risk.

    Infusion: The gene-corrected cells are infused intravenously in a single dose. They travel to the bone marrow, engraft, and begin producing CD18-expressing neutrophils and other leukocytes, ideally for the patient’s lifetime.

    Lentiviral vectors and insertional oncogenesis: the long-term risk to understand A lentiviral vector works by integrating a copy of the therapeutic gene into the patient’s genome, which is what makes the correction permanent. But integration is not perfectly targeted: the vector can insert near oncogenes (cancer-promoting genes), potentially disrupting their regulation. This risk is called insertional oncogenesis. Early-generation retroviral gene therapies for X-linked SCID caused leukemia in some patients, creating lasting concern about the category. Modern lentiviral vectors like the one used in KRESLADI are self-inactivating (SIN): the viral promoter that could drive oncogene expression is deleted after integration, substantially reducing this risk. The prescribing information for KRESLADI includes a formal warning for lentiviral vector-mediated insertional oncogenesis and requires long-term follow-up monitoring. No cases of insertional oncogenesis were observed in the Phase 1/2 trial, but with a median follow-up of 4.2 years in only 9 patients, long-term surveillance remains a post-marketing requirement. This is not a reason to avoid the therapy in a disease with near-certain early mortality without treatment, but it is a reason for enrolled families to maintain follow-up.

    The Phase 1/2 Clinical Trial: Nine Patients, Published in NEJM

    The trial supporting KRESLADI’s approval (NCT03812263) was an open-label, single-arm, multicenter Phase 1/2 study conducted at leading pediatric immunodeficiency centers including UCLA and Great Ormond Street Hospital in London. It enrolled 9 children with molecularly confirmed severe LAD-I (biallelic ITGB2 mutations, CD18 expression below 2% of normal) who lacked an available HLA-matched sibling donor.

    The primary endpoints were biomarker-based: neutrophil CD18 and CD11a surface expression at 12 and 24 months, used as surrogates for restored immune function. Secondary endpoints included safety, engraftment, infection events, and HSCT-free survival. Results were published in the New England Journal of Medicine.

    OutcomeResult
    Study population9 children with severe LAD-I, biallelic ITGB2 mutations, no HLA-matched sibling donor
    HSCT-free survival at 1 year100% (95% CI 66 to 100; p less than 0.001)
    Graft failures0 of 9
    Median follow-up4.2 years (range 3.6 to 5.7)
    Neutrophil CD18 expression (Month 12)Sustained increase in all 9 patients
    Neutrophil CD18 expression (Month 42)Sustained in all 7 patients with available data
    Neutrophil CD11a expression (Month 12)Median 45% (range 18 to 75)
    Neutrophil CD11a expression (Month 24)Median 39% (range 17 to 65)
    Patients enrolled below age 1 yearAll alive beyond 2 years of age
    Treatment-related serious adverse eventsNone reported
    Insertional oncogenesis casesNone observed (ongoing monitoring required)

    Source: Phase 1/2 clinical trial results for marnetegragene autotemcel in LAD-I. New England Journal of Medicine. NCT03812263.

    The 100% HSCT-free survival figure warrants careful interpretation alongside the confidence interval (66 to 100%). With only 9 patients, the lower bound of that confidence interval means the true survival rate could theoretically be as low as 66%, which is not a negligible uncertainty. The FDA’s accelerated approval based on biomarker data rather than confirmed long-term clinical outcomes reflects this: the agency considered the surrogate endpoints (CD18 and CD11a expression) sufficiently likely to predict clinical benefit given the biological coherence and the disease’s natural history, while requiring confirmatory data through post-marketing studies.

    What the 4.2-year median follow-up confirms is durability of the biomarker response: all 7 patients with data available at month 42 maintained sustained neutrophil CD18 expression. The correction appears stable across the observation period, which is among the longest available for any lentiviral hematopoietic gene therapy in a primary immunodeficiency.

    Vinay Prasad, MD, MPH, Chief Medical and Scientific Officer and Director of the FDA Center for Biologics Evaluation and Research, stated at the time of approval that today’s accelerated approval provides a breakthrough treatment for pediatric patients with severe LAD-I, the first FDA-approved gene therapy to treat this disease.

    KRESLADI vs. Allogeneic HSCT: Understanding the Comparison

    The most meaningful clinical comparison for KRESLADI is not placebo. In a disease with near-certain early mortality, a placebo-controlled trial would be unethical. The relevant comparison is allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor, the only prior curative approach.

    FeatureKRESLADI (gene therapy)Matched sibling HSCT
    Donor requiredNo, uses patient’s own cellsYes, HLA-matched sibling
    AvailabilityAll eligible patients without matched siblingApproximately 25 to 30% of patients have matched sibling
    GVHD riskNone (autologous)Significant, especially with mismatched donors
    Graft failure risk0 of 9 in trialHigher with mismatched; lower with matched sibling
    Conditioning requiredYes, full myeloablativeYes, myeloablative or reduced-intensity
    Insertional oncogenesis riskSmall but real (lentiviral vector)None
    Long-term follow-up dataMedian 4.2 years (n=9)Decades; large registry data available
    Regulatory statusFDA accelerated approval (March 2026)Standard curative approach (first-line when donor available)

    The comparison highlights that KRESLADI is approved specifically for the gap population, those without an available HLA-matched sibling donor. It does not replace matched-sibling HSCT, which remains the standard approach when a donor is available. For families without that option, gene therapy now provides a curative path that did not previously exist.

    The ongoing clinical evolution of HSCT is also worth noting. Haploidentical transplantation, using a partially matched donor such as a parent, is increasingly feasible through improved graft manipulation techniques and is being evaluated as an alternative for patients without matched siblings. The availability of KRESLADI creates an additional option alongside these evolving transplant approaches, giving clinicians and families more to consider.

    Safety: What to Know Before Treatment

    No treatment-related serious adverse events were reported in the Phase 1/2 trial, a notable finding given the severity of the conditioning regimen required. Most adverse reactions reflected the expected effects of myeloablative conditioning rather than the gene therapy product itself.

    Common adverse reactions in the trial population included: mucositis, upper respiratory tract infection, viral infection, febrile neutropenia, skin lesions, nausea and vomiting, rash, pyrexia, device-related infection, decreased blood counts (hemoglobin, platelets, neutrophils, leukocytes), and elevated liver enzymes (AST, ALT).

    The prescribing information includes formal warnings and precautions for:

    • Serious infections: susceptibility increases during the myeloablative conditioning period before engraftment is established
    • Veno-occlusive disease (hepatic VOD): monitor liver function tests during the first month following infusion
    • Neutrophil engraftment failure: defined as failure to achieve absolute neutrophil count of 500 cells per microliter or higher by Day 43; back-up unmodified CD34+ cells are preserved in case rescue is needed
    • Delayed platelet engraftment
    • Lentiviral vector-mediated insertional oncogenesis: long-term monitoring required
    • Hypersensitivity reactions

    What Treatment Involves: The Full Patient Journey

    For families whose child has been diagnosed with severe LAD-I and lacks an HLA-matched sibling donor, the path to KRESLADI involves a structured sequence of steps that requires specialized care at a qualified treatment center.

    Genetic confirmation first

    KRESLADI is indicated specifically for patients with severe LAD-I due to biallelic variants in ITGB2 confirmed by molecular testing, with CD18 expression below 2% of normal. Clinical diagnosis alone is not sufficient for eligibility. Genetic testing confirming the ITGB2 mutations is required.

    Specialized treatment center

    KRESLADI will be administered only at qualified treatment centers with experience in bone marrow transplantation and gene therapy. The manufacturing process, including mobilization, apheresis, ex vivo gene correction, and back-up cell preservation, requires institutional infrastructure that is not available at all pediatric centers. Rocket Pharmaceuticals indicated it plans a measured rollout to ensure quality and safety at launch.

    Timing matters

    The trial enrolled children as young as infants. Outcomes in LAD-I gene therapy, as in most gene therapies for primary immunodeficiencies, are generally better when treatment is given before significant infection-related damage has accumulated. Families who receive a diagnosis of severe LAD-I should contact a specialized immunodeficiency center promptly to discuss evaluation and next steps, rather than waiting for a clinical crisis.

    Regulatory designations

    KRESLADI received multiple FDA designations supporting its development:

    With approval, Rocket Pharmaceuticals received a Rare Pediatric Disease Priority Review Voucher, a transferable regulatory instrument that entitles the holder to priority (6-month) FDA review for a future NDA or BLA. PRVs have historically traded in the $100 to $150 million range. Rocket may use the voucher for a future program or sell it; either way, it represents a financial mechanism designed to incentivize rare pediatric drug development.

    For related coverage of other rare pediatric disease FDA approvals in 2026, see our posts on the first gene therapy for genetic deafness approved under the Rare Pediatric Disease PRV program, the UX111 gene therapy BLA for Sanfilippo syndrome now under FDA review, and the approval of navepegritide (YUVIWEL) for achondroplasia in children.

    For families whose child has been diagnosed with severe LAD-I or who are under evaluation for a primary immunodeficiency presenting with recurrent severe infections in infancy, the most important first step is early referral to a center with expertise in primary immunodeficiencies and gene therapy. The Immune Deficiency Foundation maintains a directory of immunodeficiency specialists and can connect families with clinical expertise. For questions about KRESLADI specifically, Rocket Pharmaceuticals’ medical affairs team and information on the treatment program are available through their website. The confirmatory post-marketing studies will build the long-term evidence base that the Phase 1/2 trial, while remarkable, cannot yet provide. Families who enroll in long-term follow-up contribute directly to that body of evidence.

    Sources

    FDA press release: FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I. FDA.gov. March 26, 2026.

    Rocket Pharmaceuticals press release: Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe LAD-I. March 27, 2026. ir.rocketpharma.com.

    FDA approval letter: BLA 125806/0 Approval Letter. March 26, 2026.

    KRESLADI prescribing information: KRESLADI (marnetegragene autotemcel) Prescribing Information. Rocket Pharmaceuticals; 2026.

    NEJM primary publication: Phase 1/2 clinical trial results for marnetegragene autotemcel in LAD-I. New England Journal of Medicine. NCT03812263.

    Phase 1/2 trial registration: NCT03812263. Gene Therapy for Leukocyte Adhesion Deficiency Type I. ClinicalTrials.gov.

    Pharmacy Times coverage: FDA Approves Marne-Cel, First Stem Cell-Based Gene Therapy for Pediatric Patients With LAD-I. pharmacytimes.com. March 2026.

    Rheumatology Advisor: Gene Therapy Kresladi Approved for Severe Leukocyte Adhesion Deficiency-I. rheumatologyadvisor.com. March 2026.

    BioPharm International: FDA Approval of Kresladi Expands Gene Therapy in Pediatric Rare Diseases. biopharminternational.com. April 2026.

    Disease overview: Novoa EA et al. Leukocyte adhesion deficiency-I: A comprehensive review. J Allergy Clin Immunol Pract. 2018.

    LAD-I GARD overview: Leukocyte Adhesion Deficiency Type 1. rarediseases.info.nih.gov.

    CD18 biology: CD18 integrin biology. PMC5555401.

    Lentiviral vectors: Lentiviral vectors in gene therapy. PMC6563422.

    Insertional oncogenesis: Insertional oncogenesis risk in gene therapy. PMC8709598.

    Hematopoietic stem cells: Hematopoietic Stem Cells. StatPearls. NCBI.

    Myeloablative conditioning: Myeloablative Conditioning. StatPearls. NCBI.

    Haploidentical HSCT: Haploidentical Transplantation. PMC7138706.

    HLA matching in HSCT: HLA Matching in HSCT. StatPearls. NCBI.

    Accelerated approval pathway: Accelerated Approval Program. FDA.gov.

    Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

    Patient resources: Immune Deficiency Foundation | NORD: LAD-I | Rocket Pharmaceuticals | ClinicalTrials.gov: LAD-I

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions for severe LAD-I should be made in consultation with a board-certified pediatric immunologist or hematologist at a center with expertise in gene therapy and primary immunodeficiencies. KRESLADI received accelerated approval; continued approval may be contingent on confirmatory post-marketing study results.